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Trauma to the skin in the form of severe wound, particularly burns, can facilitate 
colonization of potentially life threatening bacterial infections. To prevent infections 
of the wounded area, antimicrobial agents are recommended as standard treatment. 
Topical administration of antimicrobial agents, such as mupirocin, can provide local 
therapy, while avoiding the risks of systemic administration. Mupirocin-in-liposomes-
in hydrogels were proposed as advanced delivery system for this purpose. Up to now, 
no liposomal mupirocin for topical administration has been reported. Chitosan was 
selected as hydrogel matrix due to its biodegradability and in-built antimicrobial and 
wound healing potentials.  
Phosphatidylcholine liposomes containing mupirocin, namely non-sonicated and 
sonicated liposomes, were characterized for vesicle size and size distributions. Non-
sonicated vesicles entrapped in average 74 and sonicated 49 % of mupirocin calcium, 
respectively. Sonication reduced the original vesicle size from around 1 micron down 
to 135 nm. Liposomes (10 %, w/w) were incorporated in chitosan hydrogels and 
liposomal hydrogels evaluated for their textural properties. Hydrogels were found to 
exhibit satisfactory adhesiveness and cohesiveness, with corresponding stability 
profile. Microbiological assessment confirmed antibacterial properties of liposomally 
entrapped mupirocin incorporated in hydrogels. In vitro and ex vivo (on pig skin) drug 
release profiles of various formulations containing mupirocin were performed on 
Franz diffusion cells. Liposomal hydrogels were compared with marketed mupirocin 
product, Bactroban® cream. The release studies showed that liposomal size affects 
the release of the incorporated drug. Liposomal hydrogels were shown to provide 
sustained release of incorporated mupirocin. 
In conclusion, liposomal hydrogels developed for mupirocin offer the potential to 
increase retention time and provide sustained release of a drug, which are important 
parameters for improved treatment of wounds, including burns. 
___________________________________________________________ 
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1. General introduction 
 
Skin wounds are injuries to the underlying tissue in which the skin is cut, punctured 
or torn. When trauma appears in the form of a burn wound, it can affect several skin 
layers. Sever burn wounds can be a tremendously hard task to treat in burn units as 
they include increased risk of fluid loss, hypothermia, infections and impaired 
scarring (Alemdaroglu et al., 2006). Burn trauma to the skin creates a local immuno-
compromised area, leading to potentially life-threatening microbial infections. In spite 
of the advances in treatment of skin wounds, wound infections are still the major 
cause of wound-related morbidity and mortality (Dai et al., 2009).  
Successful burn therapy represents a specific challenge in respect to therapeutic 
outcome, scaring, functional and cosmetic consequences. Several promising lines in 
development of burn therapy were proposed, among which hydrogels appear to fulfill 
many of the criteria for ideal wound dressing. The ideal dressing should achieve 
permanent skin regeneration, have good functional and esthetic characteristics, 
optimal mechanical properties, be bioadhesive and possibly provide controlled release 
of active ingredients (Boateng et al., 2008). Hydrogels are water-swollen polymeric 
gels, which possess a three dimensional structure, with an ability to retain large 
amount of water. Chitosan is a natural biodegradable polymer with wound healing 
properties on its own (Bhattarai et al., 2010). Chitosan hydrogels provide a moist 
environment at wound site and exhibit bioadhesive properties. In order to ensure 
controlled release of active ingredient, liposomes bearing mupirocin were 
incorporated in chitosan hydrogels. 
Mupirocin calcium was selected as model antimicrobial drug due to its activity 
against various bacteria, commonly infecting wounded areas of skin (Bageshwar et 
al., 2010). Its additional advantage is the fact that it shows low activity against 
microorganisms in the normal skin flora. This can be seen as an advantage due to the 
skins normal defences against pathogens, will not be interfered by the selected drug 





2.1. Skin and wounds 
2.1.1. Skin structure  
The largest organ of the body is the skin. Human skin consists of three layers, namely 
the epidermis, dermis and hypodermis, respectively (Sherwood, 2007). The epidermis 
consists of several layers of epithelial cells. These layers (Figure 1), from the inside to 
the outside, are the stratum germinativum, stratum spinosum, stratum granulosum, 
stratum lucidum and stratum corneum (El Maghraby et al., 2008)  
 
Figure 1: Different layers of the epidermis (Grawkrodger, 2008) 
	  
The innermost epidermal layer consists of cells that are promptly dividing, in contrary 
to the outer layer of the epidermis, comprising of dead cells, flat in appearance. This 
latter layer is referred to as the stratum corneum (SC) or the horny layer. SC varies 
greatly in thickness, ranging from 0.8 to 0.006 mm on the palm, soles and eyelids, 
respectively. The SC may be merely 10 µm thick when it is dry, but will swell 
several-fold when in contact with water (El Maghraby et al., 2008). The epidermis is 
dependent on diffusion of nutrients from the dermis, as there is no blood supply in the 
epidermis (Sherwood, 2007). 
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Beneath the epidermis is the dermis. This layer is ranging from 3-5 mm in thickness 
(Sherwood, 2007). The dermis functions as a connective tissue layer that contains 
elastin and collagen fibres, providing the skin with ability to stretch and strength, 
respectively. Blood vessels, skin appendages, lymphatic’s, and specialized nerve 
endings are abundant in this layer. Not only is the dermis providing nutrition to the 
epidermis, it also plays a key role in temperature control. Due to the specialized nerve 
endings in the dermis, more accurately the afferent nerve fibres, dermis perceives 
pressure, pain, temperature and other somato-sensory inputs. The hair erection and 
discharge by the skins exocrine glands are controlled by the efferent nerve endings 
based in the dermal stratum (Sherwood, 2007). 
 
Figure 2: Anatomy of the skin (Goering et al., 2008) 
 
The subcutis (Figure 2) is also known as the hypodermis. The hypodermis is a loose 
layer of connective tissue that anchors the underlying tissue. Adipose tissue makes up 




2.1.1.1. Intact skin 
Human skin serves as a protective barrier against chemicals and ultraviolet light. The 
skin also serves as a shield against patogenic microorganisms. Synthesis of vitamin D 
in the epidermis, and storage of adipose tissue in the hypodermis are additional 
important features of intact skin. Healthy and intact skin is important for our health 
and well-being (Sherwood, 2007).  
The surface of intact skin has a pH value in the range of 5.4-5.9. The protetcing acid 
barrier varies in relation to both endogenous and exogenous factors. Due to the acidic 
nature of skin, several bacterial strains are normally present, which makes up the 
natural microbial flora for healthy skin (Schmid and Korting, 2006). Staphylococcus 
epidermitis, Staphylococcus aureus, and Micrococcus luteus are the most abundant 
bacteria on healthy human skin (Baron, 1996). 
Passage of external molecules through, across and via human skin can be facilitated 
by three potential pathways (Figure 3). 
 
Figure 3: Illustrating routes of penetration: 1. Through sweat glands; 2. Across 
stratum corneum; 3. Via the hair follicles (Benson, 2005) 
 
They include the pathways through the sweat ducts, via the hair follicles and the 
sebaceous glands (collectively called the appendageal route) or the passage directly 
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across the SC. It is generally accepted that the appendageal route represents 
approximately 0.1 % of the passage of drugs through the skin. The SC is considered 
to be the rate limiting step in transdermal penetration of nearly all molecules 
(Bouwstra and Ponec, 2006). 
The structure of the SC can be seen as a so-called bricks and mortar arrangement, 
were the bricks represent the keratin-rich corneocytes and the mortar represents the 
intracellular lipid-rich matrix (Benson, 2005; El Maghraby et al., 2008). 
External molecules can pass through the “brick and mortar” structure by either 
intracellular or trans cellular pathway (Figure 4). 
 
Figure 4: Illustration of the intracellular and the trans cellular route (Benson, 2005) 
 
The intracellular route (Figure 4) is now considered to be the foremost route for 
permeation of most of the drugs applied to the skin. The degree of the lipophilicity 
and the size of the molecule will play an important role for molecules passing through 
the lipid domains (Benson, 2005). 
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2.1.1.2. Injured skin and its barrier properties 
Skin injuries and chronic skin wounds, such as skin ulcers, are very serious health 
issues. It is estimated that over 1.25 million people experience burn injuries each year, 
and over 6.5 million people suffer from chronic skin wounds just in USA alone 
(Chaby et al., 2007). These injuries impair the quality of life and take up substantial 
health care resources. Improved wound therapy become the ultimate goal in wound 
therapy. There is consensus on wound therapy that for an optimal wound healing the 
wound environment should be kept moist. At the same time, the changed skin barrier 
function should be taken into account when developing dressings/drug delivery 
systems for injured skin. The lipophilic and hydrophilic properties of the skin are 
most likely to be altered when skin is injured. The pH of the skin may also be 
changed. Depending on the severity and the complexity of the damaged skin, the 
permeability of skin for various drugs might be very high (Bouwstra and Ponec, 2006; 
Chaby et al., 2007; Boateng et al., 2008). 
The protective role of the skin in holding in body fluids comes under the serious 
treath after sever burn injuries. Bacterial infections can easily get mainstay in the 
defenseless underlying tissue. Moreover, the systemic consequences of loss of water 
and plasma proteins which escape from the uncovered burned exterior are even more 
serious. The disturbances in the circulation can be life threatening (Sherwood, 2007). 
 
2.1.2. Wounds 
Skin wounds are injuries to the underlaying tissue in which the skin is cut, punctured 
or torn. Skin wounds can be divided into two classes based upon their apperance and 
ability to heal, as acute or chronic wounds, respectively. An acute wound is tissue 
injury that heals within 8-12 weeks (Boateng et al., 2008). The definition of a chronic 
wound is the injured tissue that has an impaired capability to heal up. The underlaying 
contidions for a chronic wound may be due to chemotherapy, steorid use, infections, 
arterial insufficiency, diabetes mellitus, radiation, pressure and venous insufficiency 
(Bao et al., 2009). Chronic wounds can exhibit complex microbiological consistency 
that can affect the healing process without showing any signs of underlaying infection 
(Frankel et al., 2009). Frankel et al. (2009) investigated chronic wounds and their 
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microbial flora and found a high percentage of methicillin-resistent S. aureus 
(MRSA), Pseudomonas aeruginosa and group B Streptococcus (45, 28, and 21%, 
respectively). The microbial study confirmed that wounds are prone to infections and 
that incorporation of antimicrobial agents in wound dressings is therefore 
recommended (Frankel et al., 2009).  
Burns are specific types of wounds which represent a dynamic living environment 
that will alter depending on both intrinsic factors (release of inflammatory mediators, 
bacterial proliferation) and extrinsic factors (dehydration, cooling, systemic 
hypotension). When epitelisation is delayed beyond three weeks, the healed wound 
will leave hypertrophic scarring (Papini, 2004). 
Burn wounds can be divided into several classes depending on the skin layers affected 
by the injury (Figure 5) (Hettiaratchy and Papini, 2004).  
• Epidermal burns; only affecting the epidermis, often result of sunburns. 
Blistering can occur with this type of burn, however, it is not commonly seen. 
Healing of the skin usually takes five to seven days (Papini, 2004). 
• Superficial partial thickness burns; these burns affect the epidermis and the 
underlaying upper dermis. In this type, blistering is commonly seen. Due to 
the impact on the dermal layer of the skin and the uncovered superficial 
nerves, this type of burns are painful. Healing of the skin depends on the 
compactness of skin appendages. Hairy skin heals more rapidly than hairless 
skin. Healing of the skin usually takes fourteen days (Papini, 2004). 
• Deep partial thickness burns; these burns affect the epidermis, and deeper into 
the dermis. Healing of the skin usually takes two to four weeks, and is often 
related to substantial scarring (Moss, 2010). 
• Full thickness burns; in these burns, the entire form of regenerative elements 
have been shattered. The healing of these burns occurs from the edges and is 
oftenly associated with contraction. The process of healing will take several 
weeks and the scarring will be visible (Papini, 2004). 
• Fourth-degree burns; extend further than the skin layers, down to the 
subcutaneous fat, mucles and bone (Moss, 2010). 
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Figure 5: Classification of burns based on burn depth (Hettiratchy and Papini, 2004) 
 
2.1.2.1. Wound healing 
Wound healing is a complicated biological process which comprises of four basic 
steps, namely (i) the immediate response, (ii) the inflamatory response, (iii) the 
proliferation, migration, contraction and (iv) the final wound resolution, respectively 
(Shaw and Martin, 2009). 
Immediate response: starts with a burst of damage signals (Figure 6). Wounded and 
stressed cells respond by activating signaling pathways, that leads to a 
phosphorylation cascade ending with alterations in gene expression, metabolism, and 
cell survival. With platelet activation and aggregation, the resulting formation of a 
insoluable nettwork of fibrin fibers acts not only as a plug, but also as a source of 
growth factors (Shaw and Martin, 2009). 
Inflammatory response: starts within a couple of minutes after the damage has 
occurred. The damaged blod vessels will leak out leukocytes (Figure 6). These 
speciallized immune cells will further enroll neutrophiles and macrophages from 
neighboring vessels. This process is further enhanced by nitric oxide, histamine and 
other factors as a consequence of vessel dilation. (Shaw and Martin, 2009). 
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Figure 6: Wound repair at a glance (Shaw and Martin, 2009, with permission) 
 
Proliferation, migration and contraction phase: fibroblast and epithelial cells will 
move into the area and grow to replace damaged tissue (Figure 6). Angiogenesis, the 
formation of new blod vessels, will provide the area with nutrition and assist the 
formation of granulation tissue. Lymphatic vessels will also enter the wound area. 
Myofibroblasts and fibroblasts will help to contract the wound, thus supporting the 
collagen fibre synthesis (Shaw and Martin, 2009). 
Resolution phase: is vital for renewal of the wounded tissue. Here the blood vessels 
are refined. Remodelling of the extracellular matrix is due to the equilibrium of 
collagen synthesis, processing and degradation (Figure 6). In this phase, the 
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myofibroblasts will undergo apoptosis. An imperfection of the resolution phase can 
eventually result in excessive scar tissue formation (Shaw and Martin, 2009).  
For a wound to heal properly a good blod flow and access to oxygenated blod is 
required. The nutritionus status is also an important factor affecting wound recovery. 
Infections of the recovering wound can increase the healing time and seriously affect 
the scarring (Chaby et al., 2007).  
 
2.1.2.2. Wound exudate 
Normally healing wounds have, to some extent, wound exudate containing 
endogenous materials, namely enzymes, growth factors and cytokines, that 
collaborate and play an important role in the wound healing cascade. In chronic 
wounds, due to the inflamation or infections, there is an increase in wound exudate 
formation. If wounds become infected, a change in the apperance of the exudate is 
recognizable. Exudate becomes more dense and purulent in apperance. If the wound 
is infected with strains of Pseudomonas or Proteus, a thick, green and smelly exudate 
will be produced, and for the latter, a typical ammonia smell is evident (Sussman and 
Bates-Jensen, 2007). 
 
2.2. Wound dressings 
In the past, traditional dressings such as natural and synthetic bandages, cotton wool 
and similar, were primarily used to keep the wound dry by allowing evaporation of 
wound exudates and preventing bacterial infections (Boateng et al., 2008). Nowadays, 
it is agreed among medical and pharmaceutical experts that a warm and moist wound 
environment enables faster and more successful wound healing (Harding et al., 2007).  
No single dressing is suitable for all wound types, and in addition, wound healing 
process has several different phases that cannot be targeted by any particular dressing, 
meaning that dressing types can also vary in different phases of wound healing 
(Boateng et al., 2008).  
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Dressings can be classified depending on their function in the wound (debridement, 
occlusive, etc), type of material used to produce the dressing (hydrocolloid, collagen, 
chitosan, etc) and the physical form (ointment, gels, etc) (Harding et al., 2007). The 
dressings can be further classified as the primary dressings, which make physical 
contact with the wound surface, the secondary, covering primary dressing and the so 
called island dressings (central absorbent region is surrounded by the adhesive portion 
(Boateng et al., 2008).  
 




However, many of dressing types fit all the criteria, therefore the more suitable 
classification would be into traditional and modern (providing moist wound 
environment) dressings (Boateng et al., 2008).  
An ideal wound dressing or wound covering should perform or mimic numerous 
actions of human skin, such as being not permeable to bacteria, being adhesive, 
occlusive, lasting and elastic enough for patient not to feel discomfort (Alsarra, 2009). 
Managing moisture in the wound is particularly challenging. The optimal dressing 
should be able to draw away components of wound fluid by providing good fluid-
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handling capacity while, at the same time, maintaining a moist environment. Fluid-
handling capacity is essential feature of dressings (Harding et al., 2007). 
 
Modern dressings (Table 1) offer a possibility to retain and create a moist 
environment around the wound and offer improved wound healing. They are mainly 
classified according to the material they are made of, as: 
• Hydrocolloid dressings 
• Alginate dressings 
• Hydrogel dressings 
• Semi-permeable adhesive film dressings 
• Foam dressings 
• Biological dressings 
• Tissue engineered skin substitutes (Boateng et al., 2008). 
 
New generations of medicated dressings incorporate various active ingredients, which 
possess therapeutic values, such as antimicrobials, growth factors, and various 
supplements (vitamin C for example). The most advanced dressings include systems 
able to provide controlled delivery of active substances at wound site (Boateng et al., 
2008). 
 
We focused on hydrogels as wound dressings, particularly hydrogels incorporating 





2.3. Hydrogels  
2.3.1. Hydrogels and their classification 
Hydrogels are water-swollen polymeric gels, which possess a distinct three- 
dimensional structure. They were the first biomaterials designed for clinical use. Due 
to their high water content, most hydrogels exhibit excellent biocompatibility 
(Kopecek, 2009). Hydrogels enable high retention of water, due to cross-linking with 
many hydrophilic side groups, providing the moist environment for wound healing 
and therefore, appear to be an ideal media to enhance healing of wounds (Bhattarai et 
al., 2010).  
Hydrogels can be classified on the basis of their network, namely as entangled 
networks, covalently cross-linked networks and networks obtained by secondary 
interactions (Berger et al., 2004a, b). 
For the preparation of chemically cross-linked hydrogels, radical polymerization is 
generally used, through the cross-linking of the polymeric chains in aqueous media, 
and subsequent formation of hydrogel. Physically cross-linked hydrogels do not 
require the presence of a cross-linking agent, and are formed spontaneously under 
optimal conditions. This type of hydrogels is biodegradable. Their amorphous 
hydrophilic phase is held together by hydrophobic interactions, hydrogen bonding 
and/or van der Waals forces (Jagur-Grodzinski, 2010). 
Hydrogels can also be classified according to: 
• Their source: synthetic, natural or hybrid hydrogels 
• The nature of the network: homopolymer, copolymer, interpenetrating, or 
double networks 
• Their physical structure: homogeneous, microporous and macroporous 
hydrogels 




2.3.2. Characteristics of hydrogels 
Hydrogels can be characterized by their rheological properties, their viscosity and 
viscoelastic strength, respectively (Boateng et al., 2008). Hydrogels, composed of 
hydrophilic polymers exhibit non-Newtonian pseudo plastic behavior. If the grade of 
pseudo plasticity decreases, the ability to spread on organic surfaces declines 
gradually (das Neves et al., 2009).  
In addition, more advanced hydrogels may also be divided into several categories 
depending on their sensitivity to different stimuli (bioreponsive hydrogels) or the way 
they responds to the change in the swelling state (Kopecek, 2009; Jagur-Grodzinski, 
2010). 
Temperature responsive hydrogels: are characterized by their temperature dependent 
sol-gel transition Tgel that relate to the lower critical solution temperature, meaning 
that the polymer network collapse when temperature increases, and by the upper 
critical solution temperature TP that relate to precipitation or dissipation of a gel. 
Polymers such as poly N-isopropylacrylamide, methylcellulose and pluronics display 
these properties (Kopecek, 2009; Jagur-Grodzinski, 2010).  
pH responsive hydrogels: are prepared by introducing weak acids or weak bases, such 
as acrylic acid and amines to the functional groups of the polymer. The swelling of 
the polymer is due to the changes in pKA or pKB values. Hydrogel composed of both 
weak basic and weak acidic polymer can display lowest swelling in the pH region 
around 4-5, but the swellability increases markedly in low and higher pH values 
environment (Jagur-Grodzinski, 2010). 
Analyte responsive hydrogels: are gels sensitive to the stimuli, for instance, mono and 
di-saccharides, enzymes, antigens and a variety of ions. They should be able to 
function under physiological temperature, pH and ionic strength (Jagur-Grodzinski, 
2010). 
Ion responsive hydrogels: can be made by fixing ethers, ligands of alkali and alkaline 
earth metal ions to a poly N-isopropylacrylamide based hydrogel. The Tgel are 
somewhat shifted in the preparation due to the complexation of ions by the ligands. 
The significance of the shift depends on the gel concentration and on the ions used in 
the solution (Jagur-Grodzinski, 2010). 
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2.3.3. Drug release from hydrogels 
Several factors will influence the drug release from polymer-based formulations: 
• Hydration of the polymer by liquids, particularly water 
• Swelling of the polymer to form a gel 
• Diffusion of the drug through the swollen material 
• The erosion of the gel  
 
These points will also play an important part in the controlled delivery of drugs when 
the dressing come in close contact with wound exudate (Boateng et al., 2008).  
Diffusion controlled release through the mesh of the hydrogel is one of the main 
release mechanism for many of the drugs incorporated in hydrogels. If the diffusion 
of the drug is considerably faster than the hydrogel expansion, then the swelling is 
considered to be the main mechanism of the drug release. Chemically controlled 
release of the drug is dependent on chemical reactions within the gel matrix, either by 
hydrolytic or enzymatic metabolism (Bhattarai et al, 2010). 
 
2.3.4. Hydrogels for wound management 
Among the potential advanced delivery systems serving as wound dressings, 
hydrogels appear to be among the most promising (Bhattarai et al., 2010). Hydrogels 
dressings contain significant amount of water (up to 90%) and are therefore 
recommended for moderately exuding wounds. They posses most of the 
characteristics of ideal wound dressing and are suitable for cleansing of dry, sloughy 
or necrotic wounds. In addition, they are non-reactive with biological tissue, 
permeable to metabolites, and non-irritant (Boateng et al., 2008). Hydrogels also 
promote moist healing, are non-adherent and cool the surface of the wound, resulting 
in pain reduction and high patient acceptability. They are particularly suitable to treat 
wounds in patients who cannot tolerate even reduced compression due to pain, such 
as burn patients. Moreover, they leave no reside, are malleable and enhance wound 
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re-epithelialisation. However, hydrogels should be avoided in treatment of heavily 
exuding wounds (Boateng et al., 2008). 
Although various polymeric materials are used in hydrogel formation, chitosan, 
natural origin polymer, is the main focus of many research groups. Due to its 
biocompatibility, its ability to absorb wound exudate, its film forming properties, and 
wound healing potentials, this naturally derived polysaccharide is a good candidate 
for burns therapy as well (Alsarra, 2009).  
 
By incorporating antimicrobial agents in hydrogels, wound infections can be 
prevented or combat. Several hydrogel formulations have been reported to be 
effective in this line. Even in early nineties Sawada et al. (1990) proposed an 
antimicrobial gel sheet as improved treatment for dermal burn wounds. The 
formulation caused enhanced epithelialisation, in comparison to conventional 
ointment-impregnated gauze dressing. The use of hydrogel formulations with 
antimicrobial activity may provide a lower resistance, and also a reduced hindrance to 
the wound healing process. Moreover, local drug delivery directly to the site of action 
may possibly prevail over unsuccessful systemic antibacterial treatment, due to the 
reduction in blood circulation in burn injuries (Boateng et al., 2008).  
 
Important advantage of the sustained drug delivery systems incorporated in hydrogels 
is the fact that the need for frequent change of the dressing can be significantly 
reduced. In addition, due to the nature of the polymer, and its biodegradability, 
hydrogel can be removed from the wound surface by easy washing if necessary. 
Especially in the case of chronic wounds with associated pain, this will ease the 
therapy and increase the patient compliance. Topical delivery of active substances 
using wound dressings can also prevent patient exposure to unwanted high systemic 
doses, thereby reducing the unnecessary drug load outside the wound site (Boateng et 





2.4.1. Structure of chitosan 
Chitosan (Figure 7) is a linear hydrophilic polymer made of copolymers of N-acetyl 
glucosamine linked by β(1-4) glycosidic bonds and glucosamine. Chitosan is the 
deacetylated form of chitin, a natural polysaccharide found in exoskeleton of insects, 
crustaceans, and some fungi (Montembault et al., 2005; Bhattarai et al., 2010).  
 
 
Figure 7: Structure of chitosan (Ph Eur) 
 
The main parameters influencing the characteristics of chitosan are its molecular 
weight and degree of acetylation, representing the proportion of deacetylated units. 
These parameters are dependent on the conditions applied during the chitosan 
preparation, but can also be modified at later stage (Berger et al., 2004b). 
Chitosans of different degree of deacetylation (DD) and different molecular weight 
display several advantages as gelling polymers in respect to their biological 
properties. These properties include homeostasis, stimulation of wound healing, 
potential to serve as tissue engineering scaffolds, and potential in drug delivery, 
especially controlled drug delivery (Ueno et al., 2001; Dai et al., 2009). Chitosan 
possesses positively charged amino groups and, as a result, chitosan is reported to 
have antimicrobial properties as well (Dai et al., 2009). Moreover, chitosan exhibits 
bioadhesiveness at the site of application resulting in increased retention time at the 
administration site, due to the charge at physiologic pH. The skin is known to exhibit 
negative charge and chitosan, being a cationic polymer, can bind electrostatically to 
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the skin and assure closer contact of delivery system, resulting in improved therapy 
(Berger et al., 2004a,b; Ribeiro et al, 2009).  
 
2.4.2. Biodegradability of chitosan 
Various enzymes, able to hydrolyze the linkages N-acetyl-glucosamine-N-acetyl 
glucosamine, glucosamine-glucosamine, and glucosamine-N-acetyl-glucosamine, can 
degrade chitosan. In the glycoside hydrolase18 family, there have been identified 8 
human chitinases. Three of them, namely the acidic mammalian chitinase, di-N-
acetylchitobiase and chitotriosidase exhibit enzymatic action. Chitosan given orally is 
most likely to be metabolized by the bacterial enzymes and lysozymes present in the 
large intestine. There is also possibility of diverse oxidation-reduction 
depolymerization and free radical degradation. The rate and degree of degradation are 
dependent on the DD; with lower values of deacetylation, an increase in the rate of 
biodegradation can be seen. The milieu of the gastrointestinal tract may also affect the 
degradation (Kim et al., 2008; Kean and Thanou, 2010). After intravenous 
administration it is believed that chitosan degradation profile is directly dependent on 
its molecular weight (Kean and Thanou, 2010).  
 
2.4.3. Biodistribution of chitosan 
The biodistribution of chitosan will be affected by its molecular size and charge of the 
side groups. After administering chitosan via the oral route, and the consequent 
absorption, the tissue distribution will be, for the most part, affected by the Mw. It is 
reported that increasing the Mw of chitosan, results in a decreased plasma 
concentration (Kean and Thanou, 2010). Intracellular uptake and distribution in in 
vitro conditions from a chitosan/DNA complex resulted in a 3-fold increased uptake 





2.4.4. Toxicity of chitosan 
Chitosan is, according to the Food and Drug Administration (FDA), generally 
recognized as safe (GRAS) (Weng et al., 2008). The toxicity profile is dependent on 
its Mw and its DD. When the DD is high, the toxicity is correlated with the Mw, and 
the chitosan concentration. When the DD is lower, it expresses a lower toxicity 
profile, and thereby is less affected by the Mw. Chitosan and its derivatives show 
potential in having antimicrobial activity against bacteria, fungi and parasites. Some 
of the bacteria include P. aeruginosa and S. aureus. This is also an additional 
advantage when applying chitosan drug delivery systems in skin injuries and burns. 
However, one has to consider the factors that may affect the chitosan toxicity, such as 
its purity, source, the salt form and polydispersity (Kean and Thanou, 2010). Due to 
its source of origin, chitosan may not be recommended orally to those people who are 
allergic to shellfish. 
 
2.4.5. Chitosan-based delivery systems in skin and burns therapy 
Due to its superior features in respect to wound healing potentials, chitosan has been 
prepared and evaluated in various drug delivery systems. 
Alsarra (2009) studied the wound healing properties of chitosan expressing different 
DD and Mw in respect to healing in dermal burn wounds. The chitosan formulations 
were compared with Fucidin® ointment (conventional wound treatment) and non-
treatment as a negative control. The wound contraction, the formation of epithelial 
and granulation tissue were found to be superior for the high Mw and high DD 
preparations (p < 0.05) when compared to the other treatment in respect to wound 
healing in rats. This demonstrates that chitosan possesses advantages as polymeric 
material when formulating drug delivery systems for burns therapy (Alsarra, 2009).  
Minocycline incorporated in chitosan-polyurethane film dressing showed to be 
promising in the treatment of burn wounds in rats. Chitosan with different DD (67, 
83, and 93 % (mol/mol), respectively) were prepared and evaluated. The most 
effective formulation in respect to wound healing was found to be the one consisting 
of 83 % DD (Aoyagi et al, 2007).  
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Ishihara et al. (2001) studied the wound healing properties of a photo-cross-linked 
chitosan hydrogel on full-thickness skin incision in mice. The hydrogel expressed 
enhanced wound contraction, closure and healing properties when compared to 
untreated (controls) mice (Ishihara et al., 2001). 
When considering the application of chitosan hydrogels in the skin and burn injuries, 
it is also important to evaluate its tolerability and the tissue acceptability by the 
treated species. Boucard et al. (2007) studied the third degree burns on pig skin. 
Chitosan (3 %; w/w) was dispersed in water and hydrochloric acid (37 %; w/w) was 
added to protonate the amine groups. The formulations showed full acceptability by 
the host organism. Potential induction of inflammatory cells migration and 
angiogenetic activity was also evaluated. After 100 days, the new tissue was found to 
be analogous to native (undamaged) skin, with acceptable aesthetic feature and great 
scar flexibility (Boucard et al., 2007). 
Deng et al. (2007) studied the biological properties of chitosan-gelatin sponge 
dressing in healing of wounds. In respect to different dryness of the formulation, the 
antibacterial properties were evaluated compared to cefradine, ciprofioxacin and 
penicillin (conventional antimicrobial treatment). The formulation showed stronger 
antimicrobial properties against Escherichia coli K88 than penicillin. The effect 
against Streptococcus was superior with the dressing, than to cefradine. In addition, 
the authors observed a shorter wound healing time for chitosan-gelatin sponge than 
with the control (sterile vaseline gauze) (Deng et al., 2007). 
Chitosan wound dressings with polyphosphate and silver (procoagulant and 
antimicrobial, respectively) were prepared in order to evaluate the hemostatic and 
antimicrobial properties of the dressing. The formulation showed accelerated blood 
clotting, augmented platelet adhesion, quicker thrombin generation, and improved 
blood absorption, (p=0.001, p=0.002, p=0.002, p< 0.001, respectively) as compared to 
the control, chitosan. Incorporating silver into the optimized chitosan-polyphosphate 
dressing resulted in superior bactericidal activity against P. aeruginosa and S. aureus 
in in vitro models. The same optimized dressing reduced the mortality in P. 
aeruginosa infected mice wounds from 90.0 to 14.3 % (Ong et al., 2008).  
Dai et al. (2009) demonstrated the efficiency of chitosan acetate dressing in treating 
P. aeruginosa and P. mirabilis infected third degree burns in mice. The topical 
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chitosan dressing, compared to nanocrystalline dressings and untreated (control) mice 
expressed survival rate of 73.3, 27.3 and 13.3 %, respectively for the P. aeruginosa 
infected group. For the P. mirabilis infected group the dressing showed survival rates 
of 66.7 in comparison to 62.5 % for the nanocrystalline dressing and 23.1 % for the 
control group. This demonstrated that chitosan wound dressings could be effective in 
preventing possibly lethal burn wound infection (Dai et al., 2009). 
 
In order to assure prolonged and controlled delivery of incorporated active ingredient, 
such as antimicrobials, the concept of delivery-system in chitosan-based vehicle is 
proposed. 
 
2.5. Liposomes as delivery systems 
2.5.1. Lipids 
Over the past fifty years there have been numerous research papers and patents on 
liposomes as drug delivery systems. Liposomes are spherical particles consisting of 
phospholipid bilayers. The choice of phospholipid used in the preparation will 
influence the properties of vesicles. Phosphatidylcholine (PC; Figure 8) is the most 
commonly used phospholipid. PC has a polar head group, represented by the 
quaternary ammonium moiety choline that is linked to the glycerol backbone by a 
phosphoric ester. The other two hydroxyl groups on the glycerol are further esterified 
with fatty acids. The phospholipid charge is neutral at physiological pH (Brandl, 
2001).  
 
Figure 8: Structure of phosphatidylcholine (Brandl, 2001; with permission) 
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2.5.2. Classification of liposomes 
Liposomes can be classified based on their structure, the method of preparation, their 
composition and application, etc (Samad et al., 2007). 
In respect to vesicle lamellarity and size, liposomes can be classified accordingly: 
• Unilamellar vesicles: all size range (UV) 
• Small unilamellar vesicles: 20-100 nm in diameter (SUV) 
• Medium unilamellar vesicles and Large unilamellar vesicles: more than 100 
nm in diameter (MUL, LUV) 
• Giant unilamellar vesicle: more than 1000 nm in diameter (GUV) 
• Oligolamellar vesicles: 100-1000 nm in diameter (OLV) 
• Multilamellar vesicles: more than several hundred nm in diameter (MLV)  
• Multi vesicular vesicles: more than 1000 nm in diameter (MV) (modified from 
New, 1990; Samad et al., 2007) 
 
However, this and similar classification should not be taken as absolute as many of 
liposome types may be classified in in-between categories. Moreover, without 
electron microscopy or small angle X-ray scattering evaluation, it is not possible to 
confirm the exact number of lamellas within the vehicle (Škalko et al., 1998b). In 
addition, one should consider the polydispersity of the vesicle population as well, as 
not all of the vesicles will express monodispersity. 
 
Based on the method of preparation, liposomes can be classified as (Samad et al., 
2007): 
1. Mechanical methods: 
A. Film method: here the liposomes are prepared by dissolving the 
phospholipid in an organic solvent, which is then removed under the vacuum. 
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When the organic solvent is evaporated, the film formed is then hydrated with 
appropriate aqueous medium. Following hydrating and swelling, the 
liposomes will be formed. The structure and the size of liposomes prepared by 
this method are the MLVs with a corresponding size around and over 1 µm in 
diameter.  
B. Methods applying sonication: performing ultrasonic irradiation on aqueous 
lipid dispersion of phospholipid vesicles will results in vesicle size reduction 
and ultimately unilamellar vesicles. Sizes (diameter) of the liposomes are 
dependent on the time and amplitude of sonication, respectively. 
 
2. Methods based on replacement of organic solvents: 
A. Reverse phase evaporation: aqueous phase containing material to be 
entrapped into the liposome is dispersed into an organic solution were the 
lipids are co-solvated. Further, rotary evaporator is used to remove the organic 
solvent. The system is then purged with nitrogen, and the lipids are again 
dissolved in the organic phase usually by using ether (diethyl or isopropyl) as 
solvent. An emulsion is obtained, and the solvent is then evaporated forming a 
semisolid gel under diminished pressure. The non-encapsulated material is 
then removed from the mixture. The liposomes formed by this method are 
called reverse phase evaporation vesicles (REV), and the size and lamellarity 
corresponds to LUVs and OLVs. 
B. Solvent vaporization method: can be performed by either the use of the 
ethanol or the ether injection method. In both methods the dissolved lipids are 
injected through a fine needle into a surplus of saline or other aqueous 
medium. In the ethanol injection method the injection is done promptly, while 
in the ether injection method, the injection is performed in slow manner. The 





3. Methods based on size transformation or fusion of performed vesicles: 
A. Freeze-thawing extrusion method: Liposomes containing entrapped drug, 
prepared by the conventional film method, are frozen in water medium, left to 
thaw and stirred. Upon completing the desired number of freeze thawing 
cycles, the sample is finally extruded through desired filter. The vesicle size 
and lamellarity will depend on the number of cycles and the size of filter 
pores. 
B. Dehydration-rehydration method: Pre-manufactured liposomes are frozen 
and freeze-dried in the presence of the material to be entrapped. Rehydration 
with the appropriate media but with reduced volume results in high 
entrapment and MLVs. The vesicle size can be further reduced by various size 
reduction methods (Škalko et al., 1998b). 
 
Based on the phospholipid composition, liposomes can be classified into conventional 
liposomes, made of neutral or negatively charge phospholipids and cholesterol, or 
cationic liposomes, made of cationic lipids such as dioleoyl 
phosphotidylethanolamine. Other types may include immunoliposomes with antibody 
sequences or other recognition markers attached on their surface, and also long 
circulating liposomes, bearing polyethylene glycol (PEG) designed to avoid 
reticuloendothelial system (Samad et al., 2007). 
 
Both hydrophilic and lipophilic drugs can be incorporated in liposomes (Figure 9) and 
the drug entrapment efficiency will be dependent on the preparation method used, 
vesicle size, lipid composition and the properties of the drug (New, 1990; Škalko et 
al, 1992). Hydrophilic drugs can be entrapped into the interior aqueous part, while 
lipophilic and charged hydrophilic drugs can be incorporated within the phospholipid 
bilayer(s) by electrostatic or hydrophobic forces, or both (Honeywell-Nguyen and 
Bouwstra, 2005). Moreover, various ligands or active molecules can be attached to 




Figure 9: SUV with lipophilic drug incorporated into the phospholipid bilayer, and 
hydrophilic drug in the aqueous compartments (Hupfeld et al, 2006, with 
permission) 
 
2.5.3. Liposomes for topical application onto skin 
Liposomes can be administered by various routes of drug administration, and as this 
project focuses on the skin as administration site, skin application of liposomes will 
be discussed in more details.  
Targeting of the active ingredients for a localized effect requires full understanding of 
the skin barrier function, and in the case of skin wounds, damaged skin barrier 
(Bouwstra and Ponec, 2006).  
Although the consensus whether intact liposomes can penetrate into the skin remains 
to be a challenge, recent review proposed the following mechanisms: 
The three possible mechanisms described for liposomal penetration of the skin 
• Lateral diffusion; involving lipid exchange via molecular diffusion 
• Passage via trans-epidermal osmotic gradient, related to hydration force where 
liposomes are sucked into the epidermis 
	  26	  
• Passage via the pilosebaceous units (hair follicles with their associated 
sebaceous glands) (de Leeuw et al., 2009). 
 
The vesicles applied topically onto the skin provide several potential advantages. The 
liposomes can overcome some of the limitations related to oral route, such as the pH, 
food intake and the motility of the GI tract, as well as bypassing the hepatic 
metabolism (Honeywell-Nguyen and Bouwstra, 2005). 
However, our aim is to assure localized delivery of active ingredient, avoiding the 
systemic absorption. Liposomes than provide the advantage of reducing skin irritation 
by sustaining the drug release at the application site, and hydrating the epidermal 
layer (Honeywell-Nguyen and Bouwstra, 2005).  
Liposomes have also a tendency to accumulate on the stratum corneum, upper skin 
strata and in the sweat ducts, hair follicles and sebaceous glands following a 
negligible entry to deeper tissues or to the systemic circulation when applied to the 
skin exterior (El Maghraby et al., 2008; Benson, 2009; de Leeuw et al., 2009). As a 
consequence, potential reduction in serious side effects, and potential 
incompatibilities that might arise from unwanted high systemic absorption of the 
selected drug are reduced (Egbaria and Weiner, 1990). 
For drug delivery systems containing liposomes with entrapped or incorporated drug 
to be applied topically onto skin, it has been shown that a mean particle size of around 
300 nm in diameter is preferable, due to the high drug concentration and reservoir in 
deeper skin layers (Škalko et al., 1998a). Very important advantage of liposomes as 
skin delivery system lies in their ability to enhance the skin permeation of hydrophilic 
drugs, which then can increase therapeutic outcome (Škalko et al., 1998a). This is 
also true for the hydrophobic drugs, due to the amphipathic character shown by the 
liposomal carrier. Additional advantage is in stabilizing unstable drugs, which then 
have the opportunity to permeate across the skin strata undamaged (de Leeuw et al, 
2009).  
Several antimicrobial drugs for liposomal skin delivery have been studied, including 
clindamycin hydrochloride, metronidazole and amphotericin B (Škalko et al., 1992; 
Škalko et al., 1998a; Gupta et al., 2010).  
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Up to best of our knowledge, mupirocin has not been studied in topical liposomal 
drug delivery system. 
 
2.5.4. Liposomal hydrogels for topical administration onto skin 
Liposomal suspensions/dispersion are liquid in nature and will not remain at the 
administration site over longer period of time. Therefore, in order to assure the 
prolonged and controlled release of incorporated drug destined for topical application 
and mode of action, liposomal hydrogels have been proposed as promising drug 
delivery system (Pavelic et al., 2001).  
By using the right vehicle in the preparation of liposomal hydrogels, it is possible to 
maintain the original size distribution of the liposomal formulation. When applying 
formulations topically, it is important to assure proper retention time of the drug at the 
site of action, to increase the therapeutic outcome and patient compliance and 
adequacy (Škalko et al., 1998a). 
Various research groups have been studying liposomal hydrogels for topical 
administration onto vagina, eye, skin etc (Pavelic et al., 2001; Pavelic et al., 2004; 
Hosny, 2009; de Leeuw et al., 2009). 
Liposomal hydrogels and their potentials in wound therapy were studied by 
Engesland (2010) and Poorahmary (2010). They evaluated the potential of both 
chitosan and carbopol hydrogels as vehicles for liposomes incorporating 
chloramphenicol, respectively.  
In respect to in vivo evaluation of liposomal hydrogels aiming at treatment of skin 
wounds, particularly interesting work is discussed below: 
Homann et al. (2007) conducted a randomized clinical trial with a liposomal hydrogel 
in the treatment of partial-thickness burn wounds in patients (n= 43). The preparation 
was a liposomal formulation with 3 % polyvinyl-pyrrolidone iodine in a Carbomer 
940 (crosslinked acrylic acid polymer) hydrogel. The phospholipid used for the 
preparation of liposomes was hydrogenated soybean PC (3 %). The formulation was 
directly compared to conventional silver-sulfadiazine cream (Flammazine®) in 
clinical evaluation, resulting in significant reduction in healing time, 9.9 ± 4.5 versus 
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11.3 ± 4.9 days, respectively. The liposomal formulation also exhibited improved 
smoothness, elasticity and appearance of the wounded area, as compared to the 
conventional cream (Homann et al., 2007). 
Vogt et al. (2001) studied liposomal polyvinyl-pyrrolidone iodine hydrogel (acrylic 
acid polymer) in comparison to conventional chlorhexidine gauze dressing when 
addressing the rate of epithelialisation and wound healing characteristic in the patients 
receiving skin grafts after suffering from burn trauma. The postulated formulation 
displayed an improved re-epithelialisation after day eleven (96.3 versus 75.9 %) and 
day thirteen (100 versus 82.3 %), respectively. The hydrogel formulation was also 
superior to the control dressing when considering the wound-healing characteristics (p 
= 0.004).  
 
2.6. Mupirocin calcium as a model antimicrobial drug 
Mupirocin calcium (MC) (Figure 10) is a calcium salt of the antibiotic produced by 
Pseudomonas fluorescens (Sutherland et al., 1985; Goering et al., 2008). Its 
mechanism of action is by inhibiting bacterial isoleucyl transfer RNA synthetase, 
which results in blocking protein synthesis and indirectly inhibiting RNA synthesis 
(Bageshwar et al., 2010). 
 
Figure 10: Structure of mupirocin calcium (Ph Eur) 
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Mupirocin expresses a broad activity against various bacteria. Those include 
Staphylococci, together with methicillin-resistant strains (MRSA) and Streptococci. 
Haemophilus influenzae, Moraxella catarrhalis, Neisseria gonorrhoeae, Neisseria 
meningitides and Bordetella pertussis are some of the gram- negative organisms that 
mupirocin shows activity against (Sutherland et al., 1985; Echevarria et al., 2003; 
Bageshwar et al., 2010). 
The drug will undergo hydrolysis in vivo, which results in its inactivation, and the 
drug will also bind resiliently to serum (95%), thereby reducing its bioavailability. 
Due to these limitations, it is often used as a topically applied antibacterial drug. 
Mupirocin is also used nasally in infection-control programs to eradicate nasal 
colonization by MRSA. It shows low activity against members of the normal skin 
flora, including corynebacteria, micrococci and Propionibacterium spp. This can be 
seen as an advantage due to the skin normal defences against pathogens, which 
remains unaffected by mupirocin. The potent antibacterial activity of MC will be 
further enhanced in an acidic environment, and can thus be an advantage in relation to 
the acidic pH associated with the skin and its surroundings (Sutherland et al., 1985; 
Thomas et al., 2010). 
When skin is injured or traumatized in any form, mupirocin can potentially penetrate 
to deeper layers. This is also true when occlusive dressings are used, resulting in 
higher permeation. However, the skin gradually metabolises MC to the inactive major 
metabolite monic acid. The use of MC ointment has shown well acceptability and 
related side effect were reported to be negligible (Echevarria et al., 2003) 
MC is slightly soluble in water, sparingly soluble in anhydrous ethanol and in 
methylene chloride (Ph. Eur). It has a log P value at 2.7 (o/w), and a pka value of 4.7 
(www.gsk.com) 
Patients suffering from burn injury are at high risk of attracting pathogens and 
developing infections. Burn wounds colonization with S. aureus vary to a great 
extent, as well as with the severity of the burn wound, the patients age, the patients 
own nasal and pharyngeal S. auerus colonization, the health care workers and the type 
of care given by the health care professional at the centre of treatment. Burn wounds 
infected by Staphylococcus aureus have been associated with a delay in the wound 
healing process, an increased demand for surgery, and a longer hospital residence. 
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Administering nasal mupirocin to patients with high risk of developing the infections, 
may contribute to reduced risk of wound colonization with S. aureus (Kooistra-Smid 
et al., 2008).  
Evaluation of the efficacy of mupirocin ointment in MRSA burn wound infection, 
showed total elimination of MRSA in all wounds treated (59 patients), moreover, the 
treatment was well tolerated by all patients. The study also recommended mupirocin 
ointment for patients suffering from burns (< 20 % of total body surface) when other 
conventional therapy has failed to eradicate the infection, however the time period for 






















3. Aims of the study 
	  
The main aim of the study was the development of topical formulation for mupirocin 
to be applied in treatment of wounds, particularly burns. There are no literature data 
available on liposomal mupirocin for topical administration. Hydrogels are one of the 
most promising wound dressings, and chitosan hydrogels offer additional advantage 
of chitosan itself having wound healing and antimicrobial properties. Mupirocin-
containing liposomes incorporated in hydrogels were expected to provide sustained 
release of incorporated drug, very important feature in improved wound therapy. 
Specific aims, in more details, were: 
• Development of liposomal formulation for mupirocin though optimization of 
preparation method, entrapment efficiency and vesicle size 
• Development of liposomes-in-hydrogels delivery system and its optimization 
through evaluation of its textural properties 
• Antimicrobial evaluation of liposomal hydrogels based on the antimicrobial 
activity of incorporated mupirocin 
• Evaluation of liposomal hydrogels based on the in vitro release profile (Franz 
diffusion cells) of incorporated mupirocin 
• Evaluation of liposomal hydrogels based on the ex vivo release profile on pig 
skin 
• Comparison of antimicrobial and drug release characteristics between 
marketed product containing mupirocin (Bactroban® cream) and liposomal 






4. Materials and Methods 
 
4.1.1. Materials 
Acetic acid (glacial) GR for analysis, Merck, Darmstadt, Germany (K25892763 846 
1.00063.1000)  
Acetonitrile, CHROMASOLV® for HPLC, gradient grade, Sigma-Aldrich, Chemie 
GmbH, Steinheim, Germany (Lot SZBA119B 34851)  
Ammonium acetate, UWR BDH PROLABO, Leuven, Belgium (Product 21200.264, 
Batch 09C100004) 
Bacteria; Bacillus subtilis (ATCC 6633), Escherichia coli (ATCC 25922), 
Enterococcus faecalis (ATCC 29212), Micrococcus luteus (ATCC 9341), 
Staphylococcus aureus (ATCC 25923), Staphylococcus epidermidis (ATCC 12228), 
Generous gift from Research Group in Microbiology, Molecular and Pharmaco-
epidemiology, Department of Pharmacy, University of Tromsø, Norway 
Bactroban 2 % (w/w) cream, (base containing benzyl alcohol cetomacrogol 1000, 
cetyl alcohol, liquid paraffin, phenoxy ethanol, stearyl alcohol, xanthan gum and 
purified water), GlaxoSmithKline, Barnard Castle, UK (Part. no 000701) 
Chitosan, high molecular weight, Sigma-Aldrich Chemistry, St Luis, USA 
(MKBD1916V 419419-250G) 
Cuprophan sheets, dimensions: 250 mm x 250 mm, molecular weight cut-off 10000 
Daltons, Medicell International Ltd, London, UK (Code CUP.03.001) 
Dialysis tubing, Molecular weight cut-off 12-14000 Daltons, Medicell International 
Ltd, London, UK (Visking code DTV12000.01.000) 
Diluted Bactroban (ex tempore), Excipients: cetomacrogol 1000, Apotekproduksjon 
AS, Oslo, Norway (322156 ANR: 4D018/1), cetyl alcohol Apotekproduksjon AS, 
Oslo, Norway (304824 ANR: 2D107/7), liquid paraffin, Norwegian Medicinal Depot, 
Oslo, Norway (ANR: 3H066/3), stearyl alcohol, Merck Darmstadt, Germany 
(K502377802 8.07680.1000) and purified water 
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Distilled water 
E-test MU MUPIROCIN (0.064-1024 µg/ml) Biomèrieux SA, Lyon, France (Lot 
516308430, Ref 516308) 
Folded capillary cells, Malvern Instruments Limited, Malvern, UK (DTS 1060 
09/10/09/314) 
Glycerin, anhydrous pure, Merck Darmstadt, Germany, (K29746193 142, 
1.04093.1000) 
Lipoid S 100 (soybean lecithin, 100 % phosphatidylcholine), a generous gift from 
Lipoid GmbH, Ludwigshafen, Germany (Lot 790631-03)  
Methanol CHROMASOLV® for HPLC, Sigma-Aldrich, Chemie GmbH, Steinheim, 
Germany (Lot SZBA119S 34860)  
MICROLITERTM Syringe 250 µl with RN Needle, Hamilton Company, Nevada, USA 
(P/N: 7657-01/00, P/N: 7806-01/00) 
Muller Hinton agar plates, Section for microbiology and infection control (SUMP), 
University hospital, Tromsø, Norway  
Mupirocin Calcium dehydrate micronized, a generous gift from GlaxoSmithKline, 
Zagreb, Croatia (Lot 41156047) 
Pig ear skin, obtained from Nortura, Målselv, Norway  
Propylene glycol, Norwegian Medicinal Depot, Oslo, Norway (331405 ANR: 
1K083/3) 




Beckmann L8-70M Ultracentrifuge, Beckmann Instruments Inc., Palo Alto, USA 
(MJM-1184-45-6L) 
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Beckmann SW 60 Ti rotor, Beckmann Instruments Inc., Palo Alto, USA (Serial nr: 
05V2693) 
Branson 5510E-MT, Bransonic ultrasonic cleaner, Danbury, USA 
B. Braun Labsonic® U, B. Braun 2000 U with needle probe tip 40 T, B. Braun 
Biotech International GmbH, Melsungen, Germany 
Büchi Waterbath B480, Büchi Vac V-500, Büchi vacuum controller B-721, Büchi 
rotavapor R-124, Büchi labortechnik, Flawil, Schwitzerland 
Distillation unit Distinction D4000, Bibby Sterilin LDT, Stone, UK 
Franz Diffusion Cell 9 mm with 5 ml receptor volume, flat ground joint, clear glass, 
clamp and stirbar, PermeGear, Hellertown, USA 
Franz Diffusion Cell 15 mm with 12 ml receptor volume, flat ground joint, clear 
glass, clamp and stirbar, PermeGear, Hellertown, USA 
Julabo heating circulator F12-ED, JULABO Labortechnik GmbH, Seelbach, Germany 
(10155866) 
MS2 Mini shaker, Chiron AS, Trondheim, Norway 
NICOMP Submicron particle sizer, model 370, Nicomp Particle Sizing system, 
Langhorne, USA 
PermeGear V6A Stirrer, PermeGear, Inc., Hellertown, USA 
Sonics High Intensity Ultrasonic Processor, 500 Watt model with temperature 
controller, probe horn 13 mm (diameter), Sigma-Aldrich, Chemie GmbH, Steinheim, 
Germany (Z513253-1EA, MW09055, Batch 3110)  
TA.XT.Plus Texture Analyser, Stable Microsystems, Surrey UK. Backward Extrusion 
Rig A/BE, Stable Microsystems, Surrey, UK 
Waters 2690, Separation module, Waters 996 Photodiode Array Detector, Waters 
Milford, USA; with XTerraTM RP18 5 µm (3.9*150 mm) and XTerraTM RP18 5 µm 
Guard Column (3.9*20 mm) from Waters, Dublin, Ireland 
Zetasizer Nano Z 2600, Malvern Instruments Limited, Malvern, UK (MAL 1037062) 
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4.1.3. Computer programs 
High Performance Liquid Chromatography: Millennium 32 Chromatography 
Manager (4.0) 
Photon correlation spectroscopy: CW 388 version 1.68 
Texture Analyser: Texture Exponent, 32 (3.0.5.0) Stable Microsystems, Surrey, UK 
Zeta potential: Zeta potential report version 2.2, Malvern Instruments Limited, 
Malvern, UK 
 
4.2. Liposomal characterisation 
4.2.1. Preparation of liposomes with mupirocin (MC) 
Mupirocin (5, 10 and 20 mg, respectively) was dissolved together with Lipoid S 100 
(200 mg) in excess methanol. The organic solvent was evaporated in a rotavapor for 
at least 20 min at 100 mmHg (45 °C and 50 rpm), and then for additional 45 min at 45 
mmHg (45 °C and 50 rpm). The obtained film was then re-suspended in 10 ml of 
distilled water. Votex was used to equally dislodge the film when needed. The 
liposomes were stored in a refrigerator for at least 24 hours before further use and 
characterization. 
 
4.2.2. Entrapment efficiency determination 
To determine the entrapment efficiency (EE) for MC, the unentrapped MC was 
separated from liposomes by ultracentrifugation and dialysis.  
Ultracentrifugation: Liposomes were centrifuged in Beckman-L8-70M 
ultracentrifuge for 90 min at 10 °C and 32000 rpm. The pellet formed upon 
ultracentrifugation was re-suspended in 1 ml of distilled water. From both the 
supernatant and the pellet, a sample of 100 µl was further dissolved/diluted in 10 ml 
of methanol (total volume) and used in HPLC analysis. 
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Dialysis: Dialysis was performed in a dialysis tubing. One ml of sample was dialysed 
against 200 and 400 ml of distilled water for 24 hours, respectively. One hundred µl, 
of both liposomal suspension and dialyzate, were further dissolved/diluted in 10 ml of 
methanol (total volume) and used in HPLC analysis. 
 
4.2.3. HPLC analysis  
The HPLC method applied was based on the method described by Echevarria et al. 
(2003), with slight modification. To obtain standard curves in both water and 
methanol, the stock solution of MC was prepared in a concentration of 40 µg/ml. 
Thirteen standard solutions of 0.2, 0.4, 0.5, 0.6, 0.8, 1, 2, 4, 6, 8, 10, 15 and 20 µg/ml 
MC were prepared by diluting the stock solution with appropriate volumes of 
acetonitrile and water (1:10; v/v). The mobile phase consisted of acetonitrile and 
ammonium acetate (0.05 M) in ratio of 27.5:72.5 (v/v), adjusted to pH 6.3 with 
hydrochloric acid. The mobile phase was filtered through a 0.2 µm pore size filter 
prior to analysis. The flow rate was set to 1 ml/min, and photodiode array detector set 
at 228 nm. The column temperature was set at 30 °C, and the sample temperature was 
set at 25 °C during the separation process. The run time was 9 min and the volume 
injected was 20 µl. All analyses were performed in triplicates, respectively. 
Data asset and management were performed by the help of a Compaq computer using 
Millennium 32 Chromatography Manager (4.0). 
 
4.2.4. Particle size analysis 
Photon correlation spectroscopy, also called dynamic light scattering, was used to 
determine the particle size distribution. Determination was performed on the 
NICOMP Submicron Particle Sizer model 370, operational by a helium-neon laser 
(632.8 nm) at an angle of 90 degrees and a temperature at 24 °C ± 1 °C. To 
circumvent any contamination with particles from the surrounding milieu, sample 
preparation was carried out in an uncontaminated area using particle-free equipment. 
Preparation and all samples handling were performed in a laminar airflow bench. Test 
tubes were filled with distilled water and sonicated for 20 minutes using an ultrasonic 
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bath, and further rinsed with filtered water (0.2 µm pore size syringe filter) before 
use. The sample was diluted empirically with freshly filtered water until an intensity 
of 250-350 kHz was obtained (Hupfeld et al., 2006). 
 
4.2.5. Size reduction of liposomes 
Liposomes were transferred to a 2 ml round bottom vial and placed on ice bath. The 
needle probe tip of sonicator was fixed in a vial, and positioned in the centre of the 
volume. Vesicle suspensions were exposed to ultrasonic irradiation with an output of 
50 Watt for a continuous cycle of 5 min to obtain desired particle size.  
Due to the technical problems, we needed to change the type of sonicator used in 
particle size reduction. Therefore, for preparation of liposomes incorporated in 
chitosan gels for in vitro and ex vivo release study on Franz diffusion cells (FDC), the 
optimized sonication time on a new sonicator (Sonics High Intensity Ultrasonic 
Processor) was set to a continuous cycle of 25 s with amplitude at 40 %, respectively. 
These conditions corresponded, in respect to the particle size of obtained vesicles, to 
the conditions of previously applied sonicator. 
 
4.2.6. Zeta potential  
Zeta potential (ZP) was measured on Zetasizer Nano Z 2600 to assess stability of 
liposomes. 
Before performing the measurements, the cell was thoroughly rinsed with distilled 
water and ethanol using an appropriate syringe, to ensure totally wetting of the cell. 
An aliquot of 100 µl of liposomes was resuspended in freshly distilled water (total 
volume 10 ml) and added to the cell via a syringe. The number of runs for each 





4.3. Hydrogels preparation and characterization 
4.3.1. Preparation of chitosan hydrogels (empty gel) 
It is known that the gelation of chitosan occurs when it is dispersed in week acid (Cao 
et al., 2009). The method used in hydrogel preparation was based on Alsarra (2009) 
and Cao et al. (2009). Chitosan was dispersed in 2.5 % acetic acid solution (w/w) and 
glycerol (10 %, w/w) added into the mixture. Glycerol was added into mixture to 
stabilize hydrogel (Engesland, 2010). The final concentration of chitosan in acetic 
acid was 2.5 % (w/w). The mixture was manually stirred for approximately 10 min. 
The preparation was allowed to swell for 48 hours in a sealed container before further 
use.  
 
4.3.2. Preparation of liposomal chitosan hydrogels (gel-N-SL; gel-SL; gel-N-SL 
(f+e)) 
Hydrogels were prepared as mention under section 4.3.1. Liposomal chitosan 
hydrogels were prepared as follows, 10 % liposomal preparations (w/w) were 
incorporated in pre-prepared chitosan (2.5 %; w/w) hydrogels, containing 10 % (w/w) 
glycerol. Liposomal suspensions used for incorporation into hydrogels were of three 
types:  
a) non-sonicated liposomes free from unentrapped MC 
b) sonicated liposomes free from unentrapped MC 
c) non-sonicated liposomal suspension containing both free and liposomally 
entrapped MC 
Hand stirring was applied to fully disperse liposomes within (Škalko et al., 1998a) the 





4.3.3. Preparation of chitosan hydrogels containing MC dissolved in propylene 
glycol (gel-pg)  
Chitosan hydrogels were prepared as mention under section 4.3.1. MC dissolved in 
propylene glycol (pg) (10 %, w/w) was incorporated in hydrogel by hand stirring. The 
prepared hydrogels were allowed to set for 2 hours before further use.  
 
4.3.4. Textural properties of chitosan hydrogels 
Textural properties of hydrogels, namely gel cohesiveness, adhesiveness, and 
hardness, are important features of gels, in respect to gel optimization (Hurler et al., 
2010). Texture analyser TA.XT. Plus was employed to determine the textural 
properties of gels. Based on the previously recommended optimization of 
experimental set up for chitosan hydrogels (Engesland, 2010), a submerge probe disk 
(40 mm in diameter) was used and measurements conducted by the backward 
extrusion. All three types of hydrogels, namely empty chitosan hydrogel, liposomal 
chitosan hydrogel and chitosan hydrogel incorporating propylene glycol were 
evaluated. 
Before starting the experiment, the force applied and the height of the probe were 
calibrated. Sixty grams of various gels were used in the experiments. The probe was 
immersed (30 mm from the top) and left unmoved for 30 seconds. Five consecutive 
measurements with 30 seconds resting interval between each run were performed 
(Engesland, 2010). 
The experimental conditions were as followed:  
pre-test speed: 4 mm/sec;  
test speed: 4 mm/sec;  
post-test speed: 4 mm/s;  
distance 10 mm; return to the start point.  
The areas and the forces (Figure 11) were measured (Engesland, 2010). 
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Figure 11: Parameters measured in texture analysis 
 
Four parameters were recorded, namely the maximum compressing force (Force 1), 
the cohesiveness (Area 1), the minimum retracting force (Force 2) and the 
adhesiveness (Area 2) (Figure 11).  
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4.4. Stability testing 
4.4.1. Accelerated stability testing of non-sonicated (N-SL) and sonicated 
liposomes (SL) 
N-SL suspension was stored for a 30-days period in an airtight container at 40 °C. SL 
suspension was treated in the identical manner. The original vesicle size and size 
distribution was compared to the vesicle size and size distribution after the 
accelerated stability testing.  
 
4.4.2. Accelerated stability testing of empty chitosan hydrogels 
The gels were stored in an airtight container at 40 °C for a 30-days period. The 
textural properties (see 4.3.4) of freshly prepared hydrogels and hydrogels after the 
accelerated stability testing were compared and evaluated. 
 
4.4.3. Accelerated stability testing of liposomal chitosan hydrogels 
a) Non-sonicated liposomal chitosan hydrogels (gel-N-SL) were stored in an airtight 
container at 40 °C for a 30-days period. The textural properties (see 4.3.4) of freshly 
prepared hydrogels and hydrogels after the accelerated stability testing were 
compared and evaluated. 
b) Sonicated liposomal chitosan hydrogels (gel-SL) were stored in an airtight 
container at 40 °C for a 30-days period. The textural properties (see 4.3.4) of freshly 
prepared hydrogels and hydrogels after the accelerated stability testing were 







4.5. Microbiological evaluation of liposomal preparations 
4.5.1. Determination of minimum inhibitory concentration (MIC) values for MC 
on selected bacterial strains 
Prior to selecting the bacterial strains, the E- test was applied to determine the MIC 
values. Final selection of microorganisms was as follows: B. subtilis, S. epidermidis, 
E. coli, S. aureus, E. faecalis, and M. luteus. 
For each strain, bacterial suspensions were prepared with turbidity corresponding to 
that of 0.5 McFarland in a sterile 0.9 % (w/w) saline, and further inoculated on an 
agar plate (Mueller-Hinton) by the help of sterile cotton tip dipped in the suspension 
and brushed in three different directions (Simpson et al., 1995). The E- test strip was 
put on the agar with the help of a tweezer, assuring that no air was trapped underneath 
the test strip. The inoculated plates were then incubated at 37 °C for 24 hours 
(Simpson et al., 1995). The experiments were performed in triplicates, respectively.  
 
4.5.2. Zones of inhibition for selected bacterial strains 
Plates containing bacterial suspension were prepared as explained under section 4.5.1, 
but without further incubation step. The plates were divided into five different areas 




iii) Diluted Bactroban cream (d Bac-cream) (mupirocin concentration 
corresponding to the concentration in liposomal hydrogels). 
Water and empty chitosan gel served as negative controls, respectively. The same 
procedure was performed for pg and gel-pg (the drug concentration was kept identical 
as in other samples).  
Aliquot (10 µl) of each sample was inoculated on the bacteria to be tested (B. subtilis 
and S. aureus, respectively). In all tested samples, the concentration of mupirocin was 
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set to be 505 µg/ml. The plates were then incubated at 37 °C for 24 hours. The 
experiments were done in triplicates, respectively.  
 
Figure 12: Dividing zones on agar plate  
 
4.6. In vitro and ex vivo mupirocin release studies 
4.6.1. In vitro mupirocin release as determined on Franz diffusion cell system 
(FDC) 
FDC was applied to determine the release of the incorporated drug from vesicles and 
liposomal hydrogels (Gonzàlez-Paredes et al., 2010) Prior to any diffusion 
experiments, both the receptor and the donor chamber (Figure 13) were filled and 
washed with deionised water, followed by methanol, for approximately one hour. The 


















Figure 13: Schematic presentation of Franz Diffusion Cell (www.permegear.com) 
 
To assure the uniform stirring during the dialysis process, the automatic stirrers were 
applied as shown in Figure 14. 
 
Figure 14: PermeGear V6A stirrer (www.permegear.com) 
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In addition, to assure that the temperature remained to be constant and corresponding 
to physiological temperature (37 °C), the cells were connected to a heater circulator as 
illustrated in Figure 15.  
 
 
Figure 15: Circulator connection to Franz Diffusion Cell (www.permegear.com) 
 
The membranes used in the experiments, namely Sartolon polyamid (0.2 µm) and 
Cuprophan (MWCO 10.000 Daltons) were evenly cut to fit the top of the receptor 
chamber. The donor chamber was placed on top, with the joint packing in between. A 
metal clamp (Figure 15) was used to hinder any interference of air in the FDC. If air-
bobbles were detected, the cell was flipped to manage release of entrapped air.  
Samples (300 µl aliquot) of different formulations were put into the donor chamber 
with a help of plastic syringe. The receptor medium (12 ml) used was the mobile 
phase previously mentioned under section 4.2.3. At different time intervals (10, 20, 
30, 45, 60, 120, 180, 240, 420 and 1440 min) sample aliquots of 200 µl were taken 
out with a Hamilton microliter syringe, and if needed, further diluted with sufficient 
amount of receptor medium, to be analyzed in HPLC analysis. The volume of 
medium taken out of the cell was replaced with fresh receptor medium after each 
sampling point. The sampling ports were covered with quadruplicate layers of 
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parafilm, whereas the donor chambers were sealed with a rubber plug to prevent any 
contamination and evaporation of both sample and receptor medium.  
The following preparations were tested to determine the release profile of mupirocin:  
i) Bactroban 2 % cream (Bac-cream 2 %)  
ii) d Bac-cream 
iii) gel-N-SL 
iv) gel- SL 
v) gel N-SL (f+e) 




All experiments were performed in quadruplicates.  
 
4.6.2. Ex vivo release studies 
The skin slices for ex vivo release studies were prepared by scalpel sectioning, after 
removing all underlying connective and fat tissues. The prepared samples of pig ear 
skin were frozen in saline and let to thaw at room temperature prior to diffusion 
experiments. 
For ex vivo release studies on pig ear skin, FDC (9 mm) with 5 ml receptor phase 
volume were used.  
The following preparations were tested to determine the release profile for MC:  







The mupirocin concentration in all formulations was set to be 505 µg/ml. 
Based on prior experiments and in order to assure sink conditions, we decided to use 
Bac-cream as diluted sample. The diluted cream contained the same amount of 
mupirocin as equivalent to liposomal concentration of entrapped drug. In addition, to 
avoid the possible effect of diluent on release profiles, a base containing the same 
excipients as Bac-cream 2 % (60 %, w/w water, 5 %, w/w cetomacrogol 1000, 5 % 
w/w, cetyl alcohol, 5 %, w/w stearyl alcohol and 25 % w/w liquid paraffin) was used 
for dilution.  
The sink conditions were assured in all experiments. 
All experiments were performed in duplicates. 
 
4.7. Statistical evaluations 










5. Results and Discussion 
 
5.1. Liposome characterization 
The results of entrapment efficiencies and particle size distributions for liposomes 
prepared by the film method are presented in Tables 2A and 2B. The separations of 
unentrapped drug were performed by either the ultracentrifugation method (A) or the 
dialysis (B). 
 












5  73.40 ± 1.54 905.3* 1.54 104.08 ± 3.81 
10  74.79 ± 0.66 905.3* 1.60 76.89 ± 13.68 
20  68.47 ± 3.17 905.3* 1.83 76.34 ± 2.39 
* The estimated size as vesicles are too polydispersed 
All preparations contained 200 mg of lipid. The values denote the mean of 3 separate 
experiments ± SD. 
 
The drug recovery was rather low for liposomes prepared with higher starting 
amounts of mupirocin (Table 2A). Although the entrapment efficiency values were 
found to be comparable for liposomes which were centrifuged to remove unentrapped 
drug to values for liposomes dialyzed to separate the unentrapped drug (Tables 2A 
and 2B), the drug recovery were found to be lower in experiments with dialyzed 
samples. The determination of the drug content in dialyzate involves multiplication 
with dilution factor based on the total volume (several hundreds millilitres), which 
often results in lower recovery. 
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5 79.20 ± 4.03 905.3* 1.53 92.15 ± 6.56 
10 77.14 ± 1.68 905.3* 1.60 68.68 ± 15.21 
20 72.47 ± 2.29 905.3* 1.83 62.95 ± 2.68 
*The estimated size as vesicles are too polydispersed 
All preparations contained 200 mg of lipid. The values denote the mean of 3 separate 
experiments ± SD. 
 
The determined particle sizes and size distributions indicated that the liposomal 
suspensions were very polydispersed, which would affect the controlled release of the 
incorporated drug, therefore, the next step in optimizing the liposomal formulations 
was to prepare liposomes of more uniform size. We applied probe sonication as a 
method to reduce the originally large particle size of vesicles. Probe sonication is 
known to reduce the size and narrow the size distribution of heterogeneous 
populations (New, 1990). Important parameter that needs to be considered related to 
sonication is the loss of the originally entrapped drug. The loss needs to be monitored 
throughout the process. 
We tried to optimize the sonication conditions in order to prepare vesicles of more 
uniform size distributions, with most of the originally entrapped material retained in 
liposomes (data not shown). The dialysis method was applied as the separation 
method for all sonicated liposomes. 
The optimized sonication conditions resulted in liposomal populations presented in 
Table 3. 
	  50	  















5 57.33 ± 0.14 27.66 ± 3.70 8.9 85.15 ± 6.85 
10 54.31 ± 2.44 29.58 ± 2.79 18.9 63.42 ± 9.35 
20 34.96 ± 0.74 51.72 ± 1.56 16.8 62.18 ± 3.05 
The values denote the mean of 3 separate experiments ± SD. 
 
As indicated in Table 3, the loss of originally entrapped mupirocin was higher for 
liposomes for which higher amounts of drug (20 mg) were taken in preparation. For 
those liposomes, the loss was over 50 % as compared to liposomes for which 5 or 10 
mg were taken in preparation. However, one should consider the drug/lipid ratio, as 
real indicator of how much of the drug is associated with liposomes, therefore final 
ratios are included in Table 3. 
 
At the same time, it was expected that the polydispersity indexes and mean particle 
size would be significantly reduced upon sonication. The polydisersity indexes for 
sonicated liposomes were between 0.42 and 0.44 for all preparations, which is 
acceptable and indicates more uniform vesicle size distributions. 
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Figure 16: Particle size of sonicated liposomes (5 mg drug taken in preparation) 
 The values denote the mean of 3 separate experiments ± SD. 
 
As can be seen in Figure 16, the mean diameter of vesicles was significantly reduced 
upon sonication and was around 200 nm (expressed as intensity and volume 
weighted), which represents the optimal vesicle size for skin applications (Cevc, 
2004).  
Figure 17: Particle size of sonicated liposomes (10 mg drug taken in preparation) 
The values denote the mean of 3 separate experiments ± SD. 
 
Under the same conditions of sonication and same lipid amount used in liposome 
preparation, the particle size of vesicles for which preparation 10 mg of drug was used 
was found to be larger (Figure 17) than for liposomes shown in Figure 16. It is 
probably the consequence of higher drug per lipid ratio (Table 3). 
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Figure 18: Particle size of sonicated liposomes (20 mg drug taken in preparation) 
The values denote the mean of 3 separate experiments ± SD. 
 
The effect of the starting amount of the drug taken into the preparation on liposomal 
size was even more pronounced for liposomes for which preparation the highest 
amount of drug was used (Figure 18). It appears that drug incorporated in the vesicle 
bilayers represents a kind of the barrier, providing the rigidity to the bilayers and 
resisting further particle size reduction. Similar findings were reported on the effect of 
cholesterol or lipophilic compounds incorporated in lipid bilayers of liposomes, 
through an increase in membrane rigidity and resistance of vesicles to sonication (di 
Cagno et al., 2011). However, mupirocin, based on its solubility profile, is expected 
to accommodate itself in both lipophilic and hydrophilic part of liposomes. We 


















Table 4: Zeta-potential of non-sonicated and sonicated liposomes 
The values denote the mean of 3 separate experiments ± SD  
 
Zeta potential is an important indicator for repulsion forces between colloidal 
particles, and thereby may postulate the stability of liposomal preparations. If the ZP 
is highly negative or positive, the vesicles may repel each other, and thereby show 
suspension stability, whereas particles with low values for ZP often tend to aggregate 
due to diminutive repulsive forces. The ZP for liposomes is depending on the lipid 
composition used in the preparation (Gonzàlez-Paredes et al., 2010). As illustrated in 
Table 4, non-sonicated large multilamellar vesicles exhibited ZP of -30.33. This value 
can indicate rather stable liposomal preparation. However, liposomes were intended 
to be incorporated into hydrogels, in which case the protective hydrogel network can 
additionally stabilize liposomal suspensions (Pavelic et al., 2001). 
Interestingly, ZP values for sonicated liposomes, made of the same phospholipid 
composition, and expected to have similar ZP, seem to be more prone to aggregation 
as seen from lower ZP values (Table 4). This phenomenon is difficult to explain, one 
of the possible explanations could be that during sonication some of mupirocin 
released from vesicles becomes associated/attached to outer liposomal membranes, 
affecting the change in surface charge. Whether it is indeed so, remains to be further 
evaluated. 
 
Stability of liposomes is discussed in part 5.3.1. 
ZP (mV) Drug 
(mg) 
Lipid 
(mg) Non-sonicated vesicles Sonicated vesicles 
20 200 -30.33 ± 3.73 6.27 ± 0.58 
	  54	  
5.2. Hydrogel characterization  
5.2.1.Textural properties of empty chitosan gel and gel-pg 
As our aim was to develop the delivery system for improved therapy, we wanted to 
assure that textural properties of hydrogels correspond to the expected properties 
(Engesland, 2010). It is important for the delivery system to provide increased 
association with the compromised area (retention time at wound site), namely to 
prolong the contact time between the drug and the wounded site (Jones et al., 1997; 
Alsarra, 2009; Akomeah, 2010). Moreover, as chitosan itself exhibits the wound 
healing potentials, longer residence time for chitosan hydrogels at the site enables 
improved therapy (Bhattarai et al., 2010). It was therefore important to investigate gel 
cohesiveness and adhesiveness in particular (Area 1 and Area 2, respectively) in order 
to correlate those two properties to the applicability of the system as wound dressing. 
 
Table 5A: Characteristics of empty chitosan hydrogel 
	  
  
SD= standard deviation, CV= % coefficient of variation. The values are the average 
of 5 runs and are absolute. 
 
Both Area 1 (cohesiveness) and Area 2 (adhesiveness) provide an indication of 
hydrogel potential to residue at the site over longer period of time. Both were in range 
suitable for the application onto the skin (Engesland, 2010). 
 
However, we are not aiming at using empty hydrogels, and in order to assure that 
incorporation of different additives is not changing the original textural properties of 
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hydrogel to a greater extent, we evaluated the hydrogel into which propylene glycol 
was added. Mupirocin was dissolved in propylene glycol prior to its incorporation 
into hydrogel. 
 




SD= standard deviation, CV= % coefficient of variation. The values are the average 
of 5 runs and are absolute. 
 
Figure 19, along with Table 5B, illustrates the changes in original hydrogel properties 
as a result of incorporation of propylene glycol. The texture properties of hydrogel, 
namely its cohesiveness and adhesiveness, declined to some extent. The decreased 
values of the cohesiveness and adhesiveness were still in the range of acceptable 




Figure 19: Texture properties of chitosan hydrogel before incorporating pg (red) and  
after incorporating pg (black)  
 
5.3. Stability testing 
5.3.1. Liposomal stability testing 
Important parameter in characterizing liposomal formulations, particularly for smaller 
vesicle size populations, is their ability to overcome stability problems. Particularly 
interesting are the leakage of originally entrapped drug, and the aggregation, fusion of 
particles resulting in vesicle size increase (Pavelic et al., 2001). To evaluate the 
stability we applied the accelerated stability testing (one-month storage at 40 ºC). The 










Table 6: Characteristics of N-SL and SL prior to accelerated stability testing 
*The estimated size as vesicles are too polydispersed 
All preparations contained 200 mg of lipid and the starting amount of drug was 20 
mg. The values denote the mean of 3 measurements ± SD. 
 
Due to the high polydispersity index (PI) for non-sonicated vesicles, which were 
multilammelar in structure and with average diameter of around 1 µm, we could not 
detect the changes in vesicle size after the stability testing, as the PI value for non-
sonicated vesicles was over 1 (1.09). This is a clear limitation of the NICOM 
measuring device, as for the particles bigger than several hundreds nanometers and 
polydisperse in nature, the machine is not suitable. Characterization on Malvern 
instrument, such as Zetasizer, would be recommendable. However, it is expected that 
the vesicle size of non-sonicated vesicles is increasing upon storage at higher 
temperatures (Skalko et al., 1998a). 
However, when assessing the size of sonicated vesicles (Figure 20), the increase in 
the vesicle size, due to the aggregation of vesicles, was observed as expected. After 
one-month incubation at 40 °C the mean diameter was found to be 178 nm (as 
compared to 134 nm prior to testing) and the PI was measured to be 0.39, 
respectively.  
Our aim was to develop liposomal hydrogels for mupirocin, therefore, liposomes 
containing mupirocin will be incorporated within the hydrogel network, and the 












N-SL 66.54 ± 1.30  905.3* 1.01 88.33 ± 2.78 
SL 31.50 ± 5.87 133.77 ± 24.32 0.35 81.06 ± 3.46 
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are incorporated in hydrogel. Hydrogels are known to protect the original structure of 





Figure 20: Particle size on sonicated liposomal preparations before (colour) and after 
accelerated stability testing (patterned). The values denote the mean of 3 
separate measurements ± SD. 
  
 
5.3.2. Stability testing of hydrogels 
5.3.2.1. Accelerated stability testing of empty chitosan hydrogels  
To further evaluate and investigate textural properties of chitosan hydrogels, we 
performed stability testing under the accelerated stability conditions (one-month at 40 
ºC) and the corresponding results are presented in Tables 7A and 7B. 
 
Table 7A: Characteristics of empty chitosan hydrogels before stability testing 
SD= standard deviaiton, CV= % coefficient of variation. The values are the average 
of 5 runs and are absolute. 
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As can be seen from Table 7A, the measured values corresponded well to values in 
Table 5A, for the same type of hydrogels, studied earlier to determine the effect of 
additive on textural properties of hydrogels. 
 
Table 7B: Characteristics of empty chitosan hydrogels after stability testing 
SD= standard deviation, CV= % coefficient of variation. The values are the average 
of 5 runs and are absolute. 
 
The values in Table 7B indicate stability problem related to empty chitosan hydrogel. 
After one month storage at 40 °C, the hydrogel lost its original cohesiveness and 
adhesiveness. It would be interesting to identify when (in time frame) the gels textural 
properties began to decline. Although the hydrogels for wound treatment are expected 
to be stored refrigerated and the accelerated stability testing is conducted under the 
extreme conditions, the findings represent serious concern and require explanation. 
One can suspect that physiochemical properties of chitosan were affected by the 
increased temperature. The hydrogels consist of series of chemical bonds holding the 
identical side chain molecules together (Jagur-Grodzinski, 2009). One may suspect 
that some form of partial breakdown of chitosan network matrix occurred, which 
resulted in decreased viscosity of hydrogel, thereby decreasing the adhesive and 
cohesive properties of original hydrogel (Figure 21).  
	  60	  
Figure 21: Texture properties of empty chitosan hydrogel before (red) and after 
(black) accelerated stability testing 
 
Although the stability results for empty chitosan hydrogels were not satisfactory, an 
important information was determined, namely that empty chitosan hydrogels, 
without any preservative present in the composition, remained to be microbiologically 
acceptable, without any traces of microbial contamination (Figure 22). The 
observation (visual) confirms self-preservative properties of chitosan, which is an 
additional advantage when optimizing chitosan hydrogel. This is also a clearly benefit 
for wound dressings, as preservatives included in wound dressings may cause wound 






Figure 22: Empty chitosan gel after stability testing 
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In previous work by Engesland (2010) and Poorahmary (2010) an interesting 
hypothesis was proposed, namely that liposomes incorporated in hydrogels improve 
the stability of hydrogel networking. Therefore, our next step was to investigate the 
impact of both N-SL and SL on chitosan hydrogel matrix.  
 
5.3.2.2. Accelerated stability testing of chitosan hydrogels containing non-
sonicated liposomes (gel-N-SL) 
The experiments were performed with two basic purposes, one to evaluate the effect 
of incorporated liposomes on the texture properties of hydrogels, and second to 
evaluate the effect of incorporated liposomes on hydrogel stability. 
 
Table 8A: Characteristics of gel-N-SL before stability testing 
	  
	  
SD= standard deviation, CV= % coefficient of variation. The values are the average 
of 5 runs and are absolute. 
 
Table 8A and Figure 23 indicate the changes in original textural properties of 
hydrogel, the original values for Area 1 being 246, and Area 2 being 199, respectively 
(Table 7A) into decreased adhesive and cohesive properties. The findings are in 
correspondence to changes in textural properties upon addition of mupirocin-in-
propylene glycol to the prepared gel (Table 5A and 5B, respectively). The changes are 






Table 8B: Characteristics of gel-N-SL after stability testing 
 
 
SD= standard deviation, CV= % coefficient of variation. The values are the average 
of 5 runs and are absolute. 
 
However when comparing the values in Table 7B with those in 8B, interesting 
phenomenon can be seen. Gel-N-SL resisted the changes due to increased temperature 
more than the empty gels under the same conditions. This can be attributed to ability 
of liposomes to accommodate them self within the polymeric network and in a way 
stabilize the network. Although the measured values for adhesiveness and 
cohesiveness are still lower than what would be desirable, the finding is promising, 
and in line with previous reported data by Engesland (2010) and Poorahmary (2010). 
This line of research needs to be further elaborated, as it appears that liposomal 
suspensions have ability to interact with the original polymer network by preserving 
the network in certain way. It would be interesting to define whether the effect is 
dependent on the amount of liposomes added into the hydrogel (10 % w/w in our 
case) or on liposomal composition and characteristics, such as surface charge and 
similar. As the aim of our study was development of formulation for mupirocin, due 
to time constraint we did not elaborate further on those findings. 
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Figure 23: Texture properties of gel-N-SL before (red) and after (black) stability 
testing 
 
Figure 24 confirms again that no contamination of hydrogels could be visually 
observed. However, one can argue that in this case mupirocin is also present in 












5.3.2.3. Accelerated stability testing of chitosan hydrogels containing sonicated 
liposomes (gel-SL) 
To determine whether the size of incorporated vesicles affects the changes in texture 
properties of hydrogels, we performed the same experiments with hydrogels 
containing sonicated vesicle (around 135 nm in size) as previously described for non-
sonicated vesicles (size over micron). 
 
Table 9A: Characteristics of gel-SL before stability testing 
SD= standard deviation, CV= % coefficient of variation. The values are the average 
of 5 runs and are absolute. 
 
Table 9B: Characteristics of gel-SL after stability testing 
SD= standard deviation, CV= % coefficient of variation. The values are the average 
of 5 runs and are absolute. 
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Tables 9A, 9B and Figure 25 confirmed previous findings. Incorporation of sonicated 
vesicles into chitosan hydrogel seems to interfere to some degree with the gels texture 
properties, however, it appears that the effect of smaller vesicles is less pronounced 
(Table 9A) than the effect of bigger vesicles (Table 8A). In addition, smaller vesicles 
seemed to stabilize the polymer network even more than bigger vesicles (Table 8B) as 
the decrease in Area 1 and Area 2 upon stability testing is less (Table 9B). It could be 
explained by the ability of smaller vesicles to accommodate themselves better within 
the polymer network, than what would be possible for larger vesicles. This fact needs 
to be further explored. 
 








As observed earlier, hydrogel did not show any microbial contaiminations upon 






Figure 26: gel-SL after accelerated stability testing 
 
 
5.4. Microbiological evaluation of liposomal preparations 
5.4.1. Determination of MIC- values for mupirocin on selected bacterial strains 
Prior to preparing mupirocin-in-liposome-in-hydrogel formulation, able to provide 
sustained release of mupirocin in contact with wounded skin, and therefore prevent 
bacterial infections, we wanted to assure that liposomally entrapped mupirocin retains 
its antimicrobial potentials. For that purpose, we firstly determined the MIC values 
for mupirocin against predetermined bacterial strains. The selection of bacteria was 
among the most commonly tested bacteria in evaluation of antibacterial potentials of 
mupirocin (Sutherland et al., 1985; Simpson et al., 1995). The MIC values are 











Table 10: MIC values for mupirocin against selected bacteria 
	  
Bacterial strain* ATCC MIC values µg/ml 
B. subtilis (Gram positive) 6633 0.19 
S. epidermidis (Gram positive) 12228 0.13 
E. coli (Gram negative) 25922 192 
S. aureus (Gram positive) 25923 0.38 
E. faecalis (Gram positive) 29212 48 
M. luteus (Gram positive) 9341 > 1064 
* (Sutherland et al., 1985; Simpson et al., 1995).  
 
 
The MIC values obtained (Table 10) directly corresponded to the published data 
(Sutherland et al., 1985; Simpson et al., 1995).  
 
The photographs in Figure 27 are the examples of representative samples indicating 
the MIC values determined for S. aureus and B. subtilis, respectively. 
 
After assuring that our experimental set up is correct, we proceeded with the 
determination of the zones of inhibition for various formulations containing 





Figure 27: MIC values for mupirocin against S. aureus (left) and B. subtilis (right) 
 
 
5.4.2. Zones of inhibition for selected bacterial strains 
 
Table 11: Zones of inhibition as determined after 24 h incubation (n=3) 
	  











S. aureus 17.13 ± 1.96 15.23 ± 1.05** 21.57 ± 0.42 6.37 ± 0.47 - 
B. subtilis 22.23 ± 1.07* 19.03 ± 0.15* 22.97 ± 0.15 5.80 ± 0.10 - 
- indicates that no growth inhibition was observed. Mupirocin concentration in all 
formulations was 505 µg/ml. * p<0.05; ** p<0.01 
 
The zones of inhibition (Table, 11; Figure 28) varied greatly for the tested mupirocin-
containing samples. Several interesting findings need to be addressed. First important 
finding was the fact that empty hydrogel (not containing mupirocin) also inhibited the 
bacterial growth to certain degree. This again confirms previous data on chitosan 
hydrogel stability (see section 5.3.2.1.), where no microbial contamination was 
observed (1 month at 40 °C) even though hydrogels did not contain any preservative. 
Secondly, the hydrogels containing non-sonicated liposomes induced stronger 
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antibacterial response (Table 11; p<0.05) than the hydrogels containing sonicated 
vesicles. As the amount of drug in all formulations was constant, this finding was 
rather difficult to explain at this stage of research. The possible explanation can be 
related to the release of liposomally entrapped drug from liposomes, followed by the 
release from hydrogel. More comment on this proposed explanation is given in part 
5.5. As a third important finding, we confirmed that liposomal hydrogels with 
mupirocin induced similar antimicrobial effect as diluted marketed product, d Bac-
cream. Against B. subtilis, the activity of gel-N-SL was identical to diluted marketed 
sample, however gel-SL was significantly less effective than diluted Bactroban (p< 
0.05). In the case of S. aureus, the inhibition was less effective, with similar tendency, 
with the exception that gel-SL was significantly less active at the level of p< 0.01. 
 
 
Figure 28: Zones of inhibition for different mupirocin formulations (S. aureus on the 
left; B. subtilis on the right) 
 
We also wanted to compare the antibacterial activity of mupirocin incorporated in 
different vehicles not containing liposomes, to determine whether liposomes as drug 
carrier have additional beneficial effect in improving antibacterial properties of 
mupirocin. Therefore, mupirocin-in-propylene glycol, mupirocin-in-propylene glycol-

















S. aureus 17.37 ± 0.41 17.20 ± 0.22 6.13 ± 0.12 
B. subtilis 18.80 ± 0.10 17.40 ± 0.5* 5.50 ± 0.3 
Mupirocin concentration in all formulations was 505 µg/ml. * p< 0.05 
 
Figure 29: Zones of inhibition for different formulations (S. aureus, left; B. subtilis 
right) 
 
The zones of inhibition detected in these set of experiments can be compared to the 
zones measured for liposomal formulations (Table 11). Mupirocin-in-propylene 
glycol-in-hydrogel was found to be less active against B. subtilis than mupirocin-in-
propylene glycol (p<0.05).  
Liposomes, incorporated in hydrogels, as drug carrier system did neither improve nor 
hinder the antibacterial activity of mupirocin against tested bacteria. However, it 
seems that preferable type of liposomes to be incorporated in hydrogels, at least based 




5.5. In vitro and ex vivo mupirocin release studies 
5.5.1. In vitro mupirocin release as determined on FDC system 
The main objective of these studies was to evaluate release profiles of various 
formulations containing mupirocin. We wanted to evaluate the potentials of liposomes 
as drug carrier, as well as liposomal hydrogels as delivery system able to ensure 
sustained release of mupirocin. All formulation were compared to marketed product, 
in either original or diluted form (Tables 13 and 14 and Figures 30-32). 
 
Table 13: Cumulative release profile for different mupirocin formulations through 



















nd = not determined 
 
Table 14: Cumulative release profile for different mupirocin formulations through 











30 min  (%) 
Released after 
7 h (%) 
Released after 
24 h (%) 
gel- N-SL 12.45 ± 2.47 37.65 ± 8.02 43.14 ± 7.41 
gel-SL 3.85 ± 0.07 8.89 ± 0.70 9.33 ± 1.23 
Bac-cream 2 
% 
5.28 ± 0.89 21.40 ± 3.08 28.62 ± 5.00 
d Bac-cream 10.48 ± 1.47 28.94 ± 2.43 42.89 ± 2.66 
gel-pg 38.82 ± 1.90 90.46 ± 4.25  90.91 ± 4.57 
pg 97.27 ± 1.27 97.33 ± 2.40 100.03 ± 2.34 
N-SL 68.79 ± 3.09 103.17 ± 4.11 nd 
SL 79.81 ± 5.38 102.09 ± 6.37 nd 
gel-N-SL 
(f+e) 
11.04 ± 1.56 32.48 ± 3.00 33.11 ± 2.78 
Type of  
formulation 
Release after 
30 min (%) 
Release after 
7 h (%) 
Release after  
24 h (%) 
gel-N-SL 5.61 ± 0.29 15.70 ± 0.36 17.25 ± 0.61 
gel-SL 3.92 ± 0.04 10.76 ± 0.17 12.09 ± 0.57 












Figure 30: In vitro release profiles of different mupirocin formulations through 
polyamide membrane (n=4) Mupirocin concentration in all formulations 























Figure 31: In vitro release profiles of liposomally-entrapped and propylene glycol-
dissolved mupirocin through polyamide membrane (n = 4) Mupirocin 






















Figure 32: In vitro release profiles of different mupirocin formulations through 
cuprophane membrane (n=4) Mupirocin concentration in all formulations 












The release profiles of mupirocin (through polyamid membrane) from different 
formulations are presented in Figure 30. How important is the assurance of sink 
conditions through out the experiment can be observed on example of original 
Bactroban (2 %, w/w) cream and diluted Bactroban cream (diluted to the 
corresponding amount of drug in liposomal formulations). The slower release of 
mupirocin from marketed product as seen in Figure 30 is the consequence of the 
absence of sink conditions. This is very important observation for various 
bioequivalence studies, as the relationship between solubility of drug and assured sink 
conditions needs to be carefully monitored. Regarding different liposomal hydrogels, 
it is evident that the liposomal size affects the release of entrapped drug, in agreement 
with data obtained in microbiological studies (Table 11). The highest percentage of 
released mupirocin was determined for hydrogels containing non-sonicated 
liposomes. The release was significantly more than from liposomal hydrogels 
containing sonicated liposomes (p<0.01). Sonicated liposomes-in hydrogels provided 
sustained release of incorporated mupirocin, as only 9.33 % of mupirocin was 
released after 24 hours. Although from the technological point of view, it is 
impressive sustained release profile, in respect to antimicrobial potentials, the release 
is too slow and needs to be modified. The same liposomes, not incorporated in 
hydrogels, released in the same time frame all of the entrapped mupirocin (Table 13). 
We did not see significant difference between total amount of mupirocin released 
from non-sonicated and sonicated liposomes (Table 13, Figure 31). Interestingly, the 
release profiles became different once the vesicles were incorporated in hydrogles. 
The release profile from non-sonicated vesicles was almost linear with time (Figure 
31). Even more interesting is the finding that the release profiles for hydrogels 
incorporating liposomes free from unetrapped mupirocin, and the same hydrogel 
incorporating liposomally entrapped and free mupirocin differed (Figure 31). This 
indicates that liposomes, incorporated in hydrogels, play important role in defining 
the release profile of entrapped drug. The explanation of why mulitlamellar in 
structure and larger in size vesicles, incorporated in hydrogels, released the entrapped 
drug faster than smaller vesicles incorporated in hydrogels, could be related to the 
partition preferences of mupirocin. It seems that mupirocin preferably partitions itself 
(logP 2.7) from mulitilamellar vesicles into the hydrogel, from where it is released 
faster. One can suspect that MC diffuses, partitions itself, in a step-wise mode, so that 
the concentration gradient is maintained through out bilayered structure of liposomes. 
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Smaller vesicles, many of them unilamellar, could provide some form of equilibrium, 
slowing the release of a drug. The fastest and maximum release was seen for 
mupirocin-dissolved-in-propylene glycol-incorporated in hydrogel (Table 13). 
By manipulating the size and properties of liposomes intended for incorporation into 
hydrogels, it is possible to achieve desired release profile for drug entrapped in 
liposomes, incorporated in hydrogels. 
Hydrogels did not only protect the original structure of liposomes and prevent the 
leakage of liposomally entrapped drug (Skalko et al., 1998a; Pavelic et al., 2001), but 
in our case, clearly provided sustained release of liposomally entrapped drug (Table 
13, Figure 30). 
Kang et al. (2010) studied a dispersion of cationic liposomes, which were loaded with 
amphotericin B (polyene type antibiotic antifungal drug), incorporated into a 
thermosensitive gel (poloxamer 407 and poloxamer 188 at various ratio). FDC 
permeation study (0.4 µm membrane filter) revealed that the gel prolonged the drug 
release from liposomes, compared to liposomal suspension and free amphotericin 
incorporated in the gel, however the study did not indicate that liposomal gels 
sustained the release of amphotericin B, rather the opposite were observed (Kang et 
al., 2010). It is important to note that amphotericin and mupirocin vary in their 
properties, and that the hydrogels used in our experiments vary from poloxamer 
hydrogels, therefore, the experiments cannot be directly compared.  
Mulik et al. (2009) reported the superior sustained release properties of cytatabine-in-
liposomes-in-gel, in comparison to gel containing free cytarabine. The group 
attributed these observations to the sustained diffusion of drug through the gel matrix 
after the incorporated cytarabine was released from the phospholipid vesicles, and 
secondly as a consequence of the lipid bilayer stiffness.  
Paavola et al. (2000) studied liposomal ibuprofen release from poloxamer 407 gels 
through a two-compartment in vitro method, using cellulose membrane (12-14000 
MWCO) Experiments revealed cumulative release of ibuprofen, with enhanced 
prolonged release from both liposomal suspension and liposomal gel, in comparison 
to ibuprofen in solution and ibuprofen-in-solution-in-gel, respectively (Paavola et al., 
2000). 
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The ability of delivery system to prolong the release of incorporated drug provides not 
only the advantage of sustained release, and consequent reduction in frequency of 
drug administration, but reduces the side effects as rapid release of drug at the wound 
site can cause local irritancy and pain (Mulik et al., 2009). 
 
How difficult is to compare the literature data on release profiles of different drugs in 
different delivery system, and different experimental set ups, is indicated in 
comparison between release profile of mupirocin through polyamide membrane 
(Figure 30) and cuprophane membrane (Figure 32). It is evident that the type of the 
membrane used affects the release profile. However, again the tendency of sonicated 
liposomes, incorporated in hydrogels, to prolong the release more than non-sonicated 
ones is clearly seen (Figure 32).  
 
5.5.2. Ex vivo release studies 
In order to evaluate the mupirocin release profile from various formulations under the 
conditions closer to in vivo conditions, we performed diffusion experiments on pig ear 
skin (Table 15 and Figure 33).  
 
Table 15: Cumulative release profile of mupirocin from different formulations 














30 min  (%) 
Release after 
7 h (%) 
Release after 
24 h (%) 
gel-N-SL 1.15 ± 0.22 8.46 ± 0.10 14.54 ± 0.31 
gel-SL 1.22 ± 0.28  4.88 ± 1.41  7.98 ± 1.35  
N-SL 2.20 ± 0.48 39.31 ± 4.40 71.08 ± 16.82  
SL 2.16 ± 0.38  32.48 ± 3.85  57.61 ± 17.88  
d Bac-cream 0* 7.76 ± 1.49  18.86 ± 2.09 
pg 31.73 ± 1.59  78.33 ± 0.73 86.12 ± 4.03 
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Figure 33: Ex vivo release profiles of mupirocin from different formulations through 










The release profiles for mupirocin from different formulation through pig skin (Figure 
33) followed similar pattern observed for the release through polyamide membrane 
(Figure 30). The maximum release was achieved from formulation in which 
mupirocin was dissolved in propylene glycol. However, from the therapy point of 
view, such a formulation would be rapidly removed from the administration site, and 
has therefore no therapuetical relevance. Similarly, liposomal suspensions, 
particularly non-sonicated ones, released mupirocin faster and in higher amount as 
compared to liposomes-in-hydrogels formulation. The release profiles for liposomal 
hydrogels incorporating non-sonicated vesicles and diluted Bactroban were similar, 
with slowest release being again observed for sonicated liposomes-in-hydrogels 
(Figure 33). 
Liposomal hydrogels provided a mean to prolong the release of incorporated 
mupirocin. Similar observation was reported by Paavola et al. (2000) on ibuprofen 
gels tested for permeation through pig lumbar dural membrane.  
 
In vitro and ex vivo release studies performed on Franz diffusion cells provide a 
valuable information on the potentials of liposomal hydrogels to provide sustained, 
and to certain degree, controlled release of mupirocin. Moreover, liposomes can be 
design in a manner to adjust and optimize the entrapped drug release profile, which, 
together with the right choice of hydrogels, opens broad possibilities for optimization 




We were able to develop liposomal delivery system for mupirocin destined for wound 
therapy, which is, to the best of our knowledge, the first report on liposomal 
mupirocin for topical administration. By incorporating liposomes-containing 
mupirocin in chitosan hydrogels, we were able to develop advanced delivery system, 
with acceptable hydrogel adhesiveness and cohesiveness, and satisfactory stability 
profile. Moreover, liposomal mupirocin retained its antimicrobial potentials. In vitro 
and ex vivo release studies revealed that by manipulating the liposomal characteristics 
such as vesicle size, it is possible to achieve sustained release of incorporated 
mupirocin. Moreover, the comparison with marketed product Bactrocan® cream 
confirmed the potentials of liposomal hydrogels for mupirocin as promising advanced 




Short-term perspectives on developed formulation  
• Deeper insight on location of mupirocin within liposomes by more advanced 
characterization methods such as confocal microscopy for example, combined 
with X-ray diffraction methods 
• Evaluating the effect of liposomal composition, such as surface charge and 
membrane rigidity, on release profile of mupirocin 
• Performing time-kill assay to investigate in more details the antibacterial 
efficacy for liposomal mupirocin hydrogels  
• Comparing skin adhesion of liposomal mupirocin hydrogels to Bactroban 
cream in pig skin bioadhesion studies 
 
Long-term perspective on developed formulation 
• Evaluation of safety and efficiency in animal burn model 
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Trauma to the skin in form of severe burns gives rise to potentially life threatening 
bacterial infections. Mupirocin was reported to be a promising antibiotic in topical 
treatment of skin infections [1]. Liposomal mupirocin is expected to provide 
prolonged and controlled release of the drug. In order to increase the bioadhesiveness 
of the system, liposomes were incorporated in chitosan hydrogels.  
Liposomes were prepared by the film method and were either used as prepared or 
reduced in size through sonication. Vesicle size was determined by dynamic light 
scattering and entrapment efficiency of mupirocin by HPLC. Liposomal hydrogels 
were compared to Bactroban® cream in respect to drug release profiles by using 
Franz Diffusion Cells. Antibacterial efficacy was tested against several strains of 
bacteria (S. aureus, S. subtilis). Bioadhesiveness was determined on Texture 
Analyzer. 
MLV liposomes (1 µm) entrapped 74 % of mupirocin, whereas sonicated liposomes 
(200 nm) entrapped 49 %. The drug release profile was depended on the formulation 
characteristics. Microbiological evaluation confirmed antibacterial properties of 
liposomal systems for mupirocin. Liposomal chitosan hydrogel showed increased 
bioadhession in comparison to the commercially available product.  
Liposomal mupirocin shows strong potential for improved wound therapy.  
[1] Kooistra-Smid et al. (2008) Burns 34: 835-839. 
	  88	  
2. ABSTRACT Submitted  
 
	  89	  
 
	  90	  
 
